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Generation of an ABCB5-knockout human melanoma cell line using the CRISPR/Cas9 
genome editing-tool - Study of ABCB5 subcellular localization by cell 
fractionation 
  
Emilie Guérit 
  
ABC transporters are integral membrane proteins mediating the active transport of molecules 
towards the plasma membrane and playing a role in a wide variety of physiological functions of 
the cell. Many of these transporters are also implicated in cancer drug resistance. ABCB5 has been 
described as a marker of skin progenitor cells, melanoma stem cells, and limbal stem cells. It was 
reported to be a mediator of multidrug resistance in many cancers including melanoma. More recent 
data also suggest a role of ABCB5 in tumor development and progression. Although eleven 
transcripts of human ABCB5 have been identified, including two long transcripts named 
ABCB5FL (full-length) and ABCB5β, the transporter remains little characterized and its 
subcellular localization has not been validated yet. This research project is divided in two parts. 
First, it aims to generate an ABCB5-knockout human melanoma cell line to create a powerful tool 
better characterize the ABCB5 transporter. Second, it aims to use this ABCB5-knockout cell line 
to pursue the study of the ABCB5 subcellular localization. The CRISPR/Cas9 genome editing tool 
will be employed to knockout the ABCB5 gene, by removing either a fragment of 53 kb or 125 kb. 
For that purpose, high quality guide RNAs will be selected to target specific regions of the gene 
and to limit the risk of off-target effects. The ABCB5-knockout cell lines will be validated at the 
genomic level by PCR and sequencing, and at the proteic level by Western Blot. The latter will also 
serve to prove the specificity of the anti-ABCB5 antibodies. The method of cell fractionation 
described by de Duve et al. will be used to study the ABCB5 subcellular localization.We 
successfully obtained cell lines with a biallelic 53 kb deletion and cell lines with a monoallelic 125 
kb deletion in ABCB5. Both have been validated at the genomic level by PCR and sequencing, and 
the proteic validation is being performed. We performed a first set of cell fractionation on the Mel-
Juso parental cell line to optimize the method and to establish a first distribution profile of ABCB5. 
Although we have detected an enrichment of ABCB5 in the nuclear and microsomal fractions, our 
results remain hypothetical. Indeed, the anti-ABCB5 antibody used in the experiment is a 
polyclonal antibody, which recognizes many other proteins. After validating the specificity of the 
antibody by Western Blot, we will perform a second fractionation on both ABCB5-expressing and 
ABCB5-knockout Mel-Juso cell lines to strenghten the current data on the transporter localization. 
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ABC ATP binding cassette 
ATP Adenosine triphosphate 
BCRP Breast cancer resistant protein 
BRET Bioluminescence Resonance Energy Transfer 
BSA Bovine serum albumin 
CDKN2a Cyclin-dependent kinase Inhibitor 2A 
CFTR Cystic Fibrosis Transmembrane Conductance Regulator 
CRC Colorectal cancer 
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CSD Chronically sun damage 
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CXCR1 C-X-C motif chemokine receptor 1 
DMEM Dulbecco modified eagle medium 
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DNA Deoxyribonucleic acid 
DSB Double-strand break 
DTIC Dacarbazine 
EDTA Ethylenediaminetetraacetic acid 
EGF Epidermal growth factor 
FACS Fluorescence-activated cell sorting 
FL Full-length 
FSC Forward scatter 
GDLP1 Glycerol-3-phosphate deshydrogenase 1 like 
GDP Guanosine diphosphate 
GFP Green fluorescent protein 
GTP Guanosine triphosphate 
HDL High-density lipoprotein 
HDR Homology directed repair 
HIF-1α Hypoxia-inducible factor 1-alpha 
IFN Interferon 
IL Interleukin 
KNL1 Kinetochore scaffold 1 
KO Knockout 
LB Lysogeny broth 
MAPK Mitogen-activated protein kinase 
MDR Multidrug resistance 
MIT Massachusetts Institute of Technology 
MMIC Malignant melanoma iniating cell 
MRP Multidrug resistance-associated protein 
NHEJ Non homologous end-joining 
NF1 Neurofibromin 1 
NF-κB Nuclear factor-kappa B 
ORC3 Origin recognition complex subunit 3 
PAM Protospacer adjacent motif 
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PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PD1 Programmed cell death 1 protein 
PFKP Phosphofructokinase platelet 
PI3K Phosphoinositide 3-kinase 
PIP3 Phosphatidylinositol (3,4,5) triphosphate 
PTEN Phosphatase and tensin homolog 
PVDF Polyvinylidene difluoride 
RFU Relative fluorescence unit 
RGP Radial growth phase 
RHOV Ras homology family member V 
RNA Ribonucleic acid 
RSS Relative specific signal 
RT Room temperature 
RT-qPCR Real-time PCR  
SDS Sodium dodecyl sulfate  
siRNa Small interference ribonucleic 
acid 
SRA Specific relative activity 
SSC Side scatter 
STYK1 Serine/threonine kinase 1 
TALE Transcription activator-like effector 
UV Ultra-violet 
VAT1L Vesicle amine transport 1 like 
VGP Vertical growth phase 
WT Wild-type 
ZF Zinc finger  
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Introduction 
1. ABC transporters 
 
The ABC transporters are integral membrane proteins that constitute the largest family 
of transmembrane proteins. They are found in both prokaryote and eukaryote species, 
in which they mediate the active transport of a variety of molecules across the plasma 
membrane [1, 2]. These transporters are called primary transporters as the source of 
energy required for the transport of molecules against their chemical gradient is 
provided by an enzymatic reaction, i.e, the hydrolysis of adenosine triphosphate (ATP) 
[2]. 
ABC transporters are categorized as importers or exporters, depending on the 
direction of the substrate transport in- or outside the cytoplasm [3]. Exporters are 
common to all species, but importers are only found in bacteria in which they drive the 
import of essential compounds that cannot diffuse across the cell membrane such as: 
sugars, vitamins, metal ions, etc. [1]. In eukaryotic cells ABC transporters export a 
range of diverse substrates from simple ions to more complex molecules (e.g., 
peptides, lipides, hydrophobic and organic compounds, etc.) [3, 4]. 
 
In human, the ABC transporters play a role in many biochemical and physiological 
processes to maintain cell homeostasis. Furthermore, theyalso able to mediate cancer 
multidrug resistance (MDR) either in sequestering drugs in organelles or in 
transporting them out of the cell. Finally, there is a growing body of evidence to 
support a role of ABC transporters in tumor biology, which has to be furtherunderstood 
[3, 4]. 
1.1 Structure 
 
The typical structure of a full ABC transporter is represented in Figure 1 and consists 
of two transmembrane domains (TMDs) and two nucleotide binding domains (NBDs). 
The NBDs are located in the cytoplasm and bind ATP. These domains provide the 
energy required for the transport of the substrate against its chemical gradient by the 
hydrolysis of ATP. The NBDs contain two highly conserved sequences among the 
majority of ATP-binding proteins, i.e., the Walker A and B motifs [1]. In addition, 
they also contain the Q-loop that couples the NBD and the TMD together, the H-loop, 
the D-loop, and the short sequence LSGGQ, specific of ABC transporters and involved 
in nucleotide binding [2]. 
Each TMD is composed of six hydrophobic α-helices forming a transmembrane 
pore. Unlike the NBDs, the TMDs do not present any conservative sequence among 
all ABC transporters. This property is due to the domain function that consists in 
determining substrate transport specificity. However, the members of a same family 
of transporters share a similar topology and have a range of substrates closely related 
[2]. 
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Figure 1: Structure of a full ABC transporter. The conventional topology consists of two 
transmembrane domains (TMDs), each of them composed of six α-helices, and responsible for substrate 
transport specificity; two nucleotide binding domains (NBDs) for ATP binding. Figure adapted from 
Gillet et al. [5]. 
Some ABC transporters also exist as half transporters or as full transporters with 
an additional TMD at the amino-terminal side of the protein (Figure 2). Among those, 
ABCC1, C2, C3, and C6 are full transporters that contain an additional domain 
composed of five α-helices at the amino-terminal end. ABCB2, B3, B6 to B10, and 
ABCD1 to D4 are half transporters. These half transporters consist of one TMD and 
one NBD located at the carboxy-terminal side of the TMD. Finally, the ABCG family 
members are reverse half-transporters, i.e., with the NBD located at the amino-terminal 
side of the TMD. The half-transporters alone are not functional, and must homo- or 
heterodimerize to be functional [5]. 
 
 
(a) 
 
 (b) (c) 
Figure 2: Additional structures of ABC transporters (a) Structure of ABCC1, C2, C3, and C6. All 
are full transporters with an additional domain composed of five transmembrane segments. (b) Structure 
of ABCB2, B3, B6 to B10, and ABCD1 to D4. All are half-transporters with one transmembrane domain 
(TMD) and one nucleotide binding domain (NBD) located at the carboxy-terminal side of the TMD. (c) 
Structure of ABCG transporters as reverse half-transporters, i.e., with the NBD located at the amino-
terminal side of the TMD. Figure adapted from Gillet et al. [5]. 
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1.2 Catalytic cycle 
 
The majority of ABC transporters mediate the transport of substrates against their 
chemical gradient. This process requires a source of energy, which is provided by the 
hydrolysis of ATP [2]. Several models have been proposed to explain the catalytic 
cycle of ABC transporters. Although different, all of them describe some fundamental 
steps as shown in Figure 3. The substrate binds to the TMDs and two ATP molecules 
bind to the NBDs. This is followed by the hydrolysis of one ATP molecule, which 
results in the conformational change of the TMDs, allowing the release of the substrate 
from the transporter. The second molecule of ATP is then hydrolyzed for the reset of 
the transporter [6]. 
 
 
Figure 3: Schematic representation of ABC transporter catalytic cycle. The substrate binds to the 
transmembrane domains (TMDs) and two ATP molecules bind to the nucleotide binding domains 
(NBDs). First ATP hydrolysis results in the conformational change of the TMDs followed by the 
substrate release from the transporter. Second ATP hydrolysis allows the reset of the transporter. Figure 
adapted from Robey et al. [6]. 
 
1.3 Families and functions 
 
In human, 48 ABC transporters exist. They are classified into seven families denoted 
by A to G. This subdivision is based on similarities shared by each family member: 
gene structure, order of the domains, and sequence homology in the NBDs and the 
TMDs domains [1, 3]. 
The ABCA family contains the largest ABC genes. These genes code for 12 full 
transporters which are mainly implicated in lipid trafficking [3]. Among all the ABCA 
family members, ABCA1 and ABCA4 are the best described. ABCA1 mediates the 
cellular efflux of phospholipids and cholesterol. Mutations in the gene are reponsible 
for disorders of cholesterol transport and of high density lipoproteins (HDL) synthesis. 
ABCA4 transports vitamin A derivatives in photoreceptor cells and plays an important 
role in the visual cycle [1, 7]. 
The ABCB family is also called the "Multidrug resistance (MDR) family" as 
several members are involved in the mechanism of multidrug resistance against a wide 
range of compounds. The ABCB transporters are unique to the mammal species and 
consist of 11 genes coding for four full-transporters and seven half-transporters. 
ABCB1 (also known as p-glycoprotein or MDR1) has been studied for a long time and 
was the first human ABC transporter cloned and characterized by Riordan et al. in 
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1985 [8]. ABCB1 is widely expressed in the intestinal epithelium, in liver cells, in the 
cells of the proximal tubule of the kidney, but also in endothelial cells of the blood-
brain barrier and the blood-testis barrier. It principally works as drug efflux pump of a 
broad range of xenobiotics to protect cells against intracellular drug accumulation [9]. 
ABCB2 and ABCB3 both encode half-transporters. They heterodimerize and mediate 
the transport of peptides into the endoplasmic reticulum. ABCB4 and ABCB11 are 
localized in the liver and implicated in the secretion of bile acids. ABCB6, ABCB7, 
ABCB8, and ABCB10 miss an amino-terminal domain. They are expressed in the 
mitochondria where they contribute to iron metabolism. Finally the ABCB9 half-
transporter has a broad expression in testis, in which the precise function remains 
unclear [10]. The ABCB5 transporter will be further described (Section 3). 
The ABCC family, also called the "Multidrug resistance-associated protein 
(MRP) family", encodes 12 full-transporters. ABCC1, ABCC2, and ABCC3 mediate 
the transport of drug conjugated to glutathione and other organic anions [1]. ABCC4 
(MRP4), ABCC5 (MRP5) are smaller proteins missing an amino-terminal domain. 
Both transporters act as efflux transporters of small molecules involved in cellular 
signaling (e.g., nucleotides, eicosanoids, etc.) [11]. The ABCC7, known as Cystic 
Fibrosis Transmembrane Conductance Regulator (CFTR) is particular. It has the 
common architecture of the majority of ABC transporters, but it does not mediate the 
active efflux of molecules: it is a chloride ion channel that allows the transepithelial 
movement of salt and liquid and that plays a role in exocrine secretions [1, 12, 13]. 
Finally, ABCC8 and ABCC9 mainly found in endocrine cells and neurons. They form 
a complex with potassium channel subunits and contribute to the regulation of insulin 
secretion and glucose homeostasis [4, 14]. 
The ABCD family members are also called "peroxisomal ABC transporters". The 
ABCD genes encode four half-transporters that play a role in very long chain fatty acid 
oxidation in the peroxisome [1, 3]. 
The ABCE and ABCF families consist of proteins that do not function as 
transmembrane transporters. The genes code for the NBDs common to others ABC 
transporters, but lack the TMDs which are crucial to function as transporters. The 
ABCE family only contains ABCE1, an oligo-adenylate binding protein which 
promotes interferon activity in response to some viral infections. The ABCF family 
member ABCF1 is associated with ribosomes and regulate the innate immune response 
[1, 15]. 
The ABCG family is composed of six "reverse" half-transporters, i.e., with the 
NBD located at the amino terminal side of the TMD. These transporters must homo- 
or heterodimerize to form functional transporters. ABCG1 is mainly expressed in 
adipocytes and macrophages, in which it regulates cholesterol transport [1, 3, 16]. 
ABCG2, also known as the breast cancer resistant protein (BCRP), is located in the 
apical membrane of hepatocytes, epithelial cells of the small and large intestines, and 
ducts and lobules of the breast. It forms a homodimer and mediates the transport of 
steroids, bile acids, and toxins to facilitate their elimination [16]. The functions of 
ABCG3 and ABCG4 are still unclear. ABCG3 is mainly found in the thymus and 
spleen where it could transport specific peptides or hydrophobic compounds from 
lymphocytes [3]. ABCG4 might heterodimerize with ABCG1 and thereby might be 
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involved in cholesterol transport [16]. Finally, ABCG5 and ABCG8 are transporters 
of sterols. They limit their intestinal absorption and increase their biliary excretion [3]. 
1.4 Role in cancers 
 
These past few years, the interest in studying the role of ABC transporters in cancers 
has grown. It is well recognized that they are involved in the mechanism of cancer 
multidrug resistance by mediating the efflux of anticancer drugs out of the cell or their 
sequestration in organelles. However, recent studies indicate that the loss or inhibition 
of ABC transporters may influence cancer cell phenotype through modifications in 
cell proliferation, differentiation, invasion, and migration. These report suggest an 
additional drug efflux-independent role of ABC transporters in tumor biology that 
remains to be further understood [17, 18]. 
1.4.1 Multidrug resistance 
The multidrug resistance is defined as a cell that became resistant not only to the 
compound that was initially administered, but also to a wide range of compounds that 
are structurally and mechanistically unrelated [6]. This is one of the major mechanisms 
thatcauses chemotherapy failure. Each year, it leads to the death of many patients 
affected with metastatic cancer [1, 6].  
 
ABCB1 is overexpressed in different subtypes of kidney, colon, breast, and lung 
cancers [19, 20]. It confers cancer cells resistance by the efflux of a range of anticancer 
drugs such as anthracyclines, vinca alkaloïds, and taxanes [21]. ABCC1 was cloned 
for the first time in 1992 by Cole and colleagues, who demonstrated that the transporter 
was able to confer resistance to doxorubicin, etoposide, vincristine, and methotrexate. 
The transporter is overexpressed in several cancers including lung, breast, prostate, 
and childhood neuroblastoma, but its precise role in the mechanism of MDR remains 
unclear [6]. Finally, ABCG2 is overexpressed in multiple solid tumors and 
hematological malignancies showing resistance to anthracyclines [6]. However, it is 
unclear if ABCG2 is responsible of the resistance to antracyclines observed in these 
types of cancers. Studies suggest that ABCG2 could be a marker of the subpopulation 
of chemoresistant cells rather than a direct contributor to this phenotype [22, 23]. 
1.4.2 Tumorigenesis 
The role of ABC transporters in cancer biology is still little understood. However, there 
is a growing body of evidence that the ABC transporters possess an additional drug 
efflux independent role in tumorigenesis [23, 24, 25]. Several experiments on mice 
models show that the disruption of some ABC transporters alter the tumorigenesis. 
The first study was performed by Mochida et al. on a mouse model of colorectal 
cancer. They knockout the Abcb1 gene and observed a reduction in the number of 
intestinal polyps and tumour incidence [26]. More recently, the role of some ABCC 
family members in neuroblastoma genesis has been investigated. Henderson et al. 
show that the disruption of Abcc1 in a mouse model of neuroblastoma decreases tumor 
incidence and increases tumor latency. In addition, they performed a series of in vitro 
assays on neuroblastoma cells to analyze the role of ABCC1, C3, and C4 in tumor 
biology. They identified that the overexpression of ABCC1 may increase cell 
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migration and colony formation. The expression of ABCC4 promotes cell proliferation 
and clonogenicity.A low expression of ABCC3 is associated with tumor recurrence or 
death [25]. Finally, some ABC transporters are also associated with poor patient 
outcome in advanced epithelial ovarian cancer. Among those, Hedditch et al. show 
that high levels of ABCA1 in primary tumors significantly correlate with a decrease 
in patient overall survival. These data are supported by experiments performed to 
silence the ABCA1 expression in human ovarian cancer cells. The results show that 
this inhibition prevents both cell proliferation and migration. In addition, ABCC7 
expression is associated with late stage epithelian ovarian cancer. The silencing of the 
transporter in human ovarian cancer cell lines results in decreased cell migration, 
invasion, proliferation, and adhesion [27]. 
Although these reports show a link between ABC transporters and tumorigenesis, 
the deep mechanism remains obscur. Fletcher et al. suggest that this role is likely 
related to the physiological function of these transporters, i.e., efflux of endogenous 
metabolites, signaling molecules, etc. To date, the knowledge about these specific 
endogenous substrates remains limited. The emergence of metabolomic studies 
constitutes a powerful strategy to screen and identify previously unrecognized 
endogenous substrates of ABC transporters to afterwards better understand their role 
in tumor biology [23]. 
2. Melanoma 
 
Cancer is the second cause of death in Europe. Although Europe only represents 9% 
of the world population, 25% of the total of cancer cases occur in the continent. It is 
estimated that in 2018 around 3.98 million new cases of cancer will be diagnosed and 
that 1.93 million of patients will probably die from the disease [28]. 
Skin cancer is classified into three types: basal cell carcinoma, squamous cell 
carcinoma, and melanoma. Melanoma is a malignant neoplasm derived from 
melanocytes. It only represents 5% of all skin cancer cases, but its incidence has 
increased worldwide over the past 30 years. This type of cancer is the most aggressive 
form of skin cancer and is responsible for the death of many patients [29]. Ferlay et al. 
estimate that in 2018, 144,200 new cases of melanoma will be diagnosed in Europe 
and that around 27,100 people will die from the disease [28]. 
2.1 Classification 
 
Melanoma can be subdivided into non-cutaneous and cutaneous melanoma. The first 
one is less common and is mainly located near the eyes and the mucosal tissues (e.g., 
genital, anal, oral cavities, etc.). The second one is more frequent and represents 
around 90% of all melanoma cases [29]. 
Cutaneous melanoma can be distinguished between chronically and non-
chronically sun damaged (CSD and non-CSD) melanoma (Figure 4). These two forms 
differ according to their anatomical site of origin, the age at onset, the level of sun 
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exposure, and the burden and types of mutations [30]. The vast majority of CSD 
melanomas affect people older than 55 years, and are mainly found in head, neck, and 
dorsal surface of distal extremeties (i.e., sites with high levels of sun exposure). They 
are heterogenous tumors that carry a high degree of mutations in several genes such 
as: NF1, NRAS, BRAF, and cKIT. Non-CSD melanomas often originate from previous 
naevi. They affect young people (i.e., under 55 years old) and are principally located 
in the trunk and proximal extremities. They show lower burden of mutations, but are 
frequently associated with the BRAFV600E mutation [30, 31]. 
 
Figure 4: Classification of cutaneous melanomas into chronically and non-chronically sundamage 
(CSD and non-CSD) melanomas. CSD melanomas are characterized by: long-term ultraviolet (UV) 
radiations exposure, age of onset older than 55 years old, high burden of mutations, and major location 
in head, neck, and dorsal surface of distal extremities. Non-CSD melanomas mainly affect people under 
the age of 55, are often associated with the BRAFV600E mutation, and are located in the trunk and 
proximal extremities. Figure adapted from Shain et al. [30]. 
2.2 Risk factors 
 
Several parameters may increase the risk of melanoma development. Among those, 
some environmental factors may be controlled to reduce the risk of tumour 
development (e.g., the level of ultraviolet (UV) radiation exposure). However, others 
factors are directly related to host characteristics and are non-modifiable (e.g., 
ethnicity, geography, number of naevi, family history of melanoma cases, etc.) [32]. 
 
Ultraviolet exposure is a well known environmental risk factor of melanoma 
development that can be controlled by the utilisation of appropriate strategies of 
prevention [32, 33]. There are three types of UV radiations: UV-A, UV-B, and UV-C. 
These subtypes differ in their radiation emission spectrum, their absorption by the 
ozone layer, and their penetration in the skin [34, 35]. Although UV-A and -B are the 
most dangerous for humans, all have genotoxic effects. Long-term sun exposure can 
induce DNA damages by the production of DNA adducts leading to the formation of 
pyrimidine dimer mutations [36]. 
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Gender, ethnicity, and geography. Gender mainly influences the anatomic site 
of the tumor. In males, melanomas are usually located in the trunk. In females, they 
are frequently found in lower limbs [32]. In a lower extent, studies have also reported 
differences in the survival rate among men and women: the latters show a lower risk 
to develop metastases and thereby have an increased survival rate [37]. Both ethnicity 
and geography may influence the incidence of melanoma. The incidence is increasing 
among the Caucasian populations [32], with the highest rate in Australia. In contrary, 
melanoma are extremely rare among black populations, which is due to a greater 
amount of melanin that protect them from the UV-carcinogenic effects [32]. 
Number of naevi and family history. The number of melanocytic naevi and the 
family history of melanoma cases increase the risk to develop melanoma. In the first 
case, studies show that around 26% of melanomas arise from previously existing naevi 
[33, 38], and that patients with more than 100 naevi have seven-fold increased risk of 
melanoma development [39]. In the second case, previous history of melanoma cases 
in the family increases the probability to develop inherited melanoma. This subtype of 
cancer is characterized by germline mutations in the genes coding for proteins that 
regulate cell proliferation. The two most commonly mutated genes are CDKN2a and 
CDK4. These mutations predispose the patient to develop melanoma, particularly at a 
young age [38, 40]. 
2.3 Clark’s model 
 
Melanocytes are neural crest-derived cells located in the epidermis, hair follicles, uveal 
tract of the eye, meninges, and anogenital tract [30]. The physiological role of 
melanocytes consists in producing melanin pigments in response to UV-exposure. The 
synthesis of melanin is performed in specific organelles called the melanosomes. 
These organelles follow several steps of maturation from early melanosome (i.e., 
without pigments) to late melanosomes (i.e., with high melanin content). Late 
melanosomes are secreted out of the cells and are transfered to keratinocytes to protect 
them against UV radiation-induced DNA damages [30, 41]. 
The process of transformation from melanocytes to melanoma is complex and 
results from an accumulation of mutations in several genes. Different models exist to 
define the process of melanomagenesis, from a benign lesion to a more aggressive and 
invasive form. The Clark’s model (Figure 5) is widely used to describe melanoma 
development according to the degree of tumor invasion. 
The first step consists of a proliferation of melanocytes that leads to the apparition 
of a benign naevus. Mutations in the BRAF oncogene are frequently found at this stage 
in melanocytes and increase the rate of proliferation in this cell population. After an 
initial proliferation, melanocytes enter into a senescence-like state in which their 
probability to progress to melanoma remains very poor. Benign naevi have the 
tendency to involute and to disappear after the age of 50. Dysplastic naevi are classified 
into mild, moderate or severe lesion, depending on their risk of progression to 
melanoma. They are characterized by structural and cytological atypia, and by the 
acquisition of additional mutations to BRAF. Mutations in the CDKN2a and PTEN 
tumor suppressors are frequent and induce gene inactivation and loss of function. In 
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the radial growth phase (RGP), cancer cells become immortals. This step is defined as 
in situ melanoma as the cancer cells proliferation is horizontal and remains confined 
within or near the epidermis. In situ melanoma can persist during many years without 
progressing into an invasive state. In the vertical growth phase (VGF), the tumor 
invades the dermis and acquires metastatic capacity. Tumour cells gain advantages that 
promote their migration and invasion, such as the loss of E-cadherin function which 
inhibits cells adhesion. Melanoma are called metastatic melanoma once they leave the 
primary tumor site. Usually, tumour cells reach lymph nodes, before to disseminate in 
distant organs through the entire body [30, 42]. 
 
 
Figure 5: Clark’s model of melanoma development. Benign naevus: benign proliferation of 
melanocytes, frequently associated with BRAF mutations. The probability of progression from benign 
naevus to melanoma remains poor. Benign naevi very often enter into a senescence-like state which is 
followed by their involution and disparition. Dysplastic naevi show additional mutations, structural and 
cytological atypia. They can be classified into mild, moderate or severe lesion, depending on the risk of 
progression to melanoma. The radial growth phase (RGP) (in situ melanoma) is described as the 
horizontal proliferation of melanoma cells that remains confined within or near the epidermis. This state 
can persist for many years without progression. In the vertical growth phase (VGP), melanoma cells 
invade the dermis and acquire a metastatic capacity. The loss of E-cadherin function promotes cell 
migration and invasion. In metastatic melanoma, the cancer cells leave the primary tumor site and reach 
lymph nodes, blood vessels, and distant organs through the entire body. Figure adapted from E. Wong 
et al. (http://www.pathophys.org/melanoma). 
2.4 Mutations in melanoma 
 
As mentioned above, the process of melanoma development and progression is closely 
related to the acquisition of a range of mutations. These mutations either activate a 
proto-oncogene or inactivate a tumor suppressor leading to the activation of signaling 
pathways promoting cell growth, proliferation, survival, migration, and invasion. The 
RAS-RAF-MEK-MAPK and the PI3K pathways are the most commonly upregulated 
signaling pathways in melanoma. In the following paragraphs are described the genes 
highly mutated in melanoma.  
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BRAF. The BRAF oncogene is mutated in around 40 to 60% of all melanoma cases 
and is considered as the most frequent somatic mutation of the malignancy. The gene 
codes for a serine/threonine protein kinase that belongs to the RAS-RAF-MEK-MAPK 
pathway. 90% of the mutations in BRAF result from a valine-to-glutamate change at 
position 600 (called the BRAFV600E mutant). This specific mutation constitutively 
activates the MAPK pathway and promotes the ERK phosphorylation. Benign naevi 
frequently show the BRAFV600E mutation. As these naevi do not present any malignant 
properties, it is suggested that the BRAFV600E mutant alone is not sufficient to induce 
melanocytes transformation into cancer cells [29, 36, 43, 44, 45]. 
NRAS. The NRAS oncogene belongs to the RAS family of genes. The protein is a 
monomeric guanosine triphosphatase located at the plasma membrane. The protein 
physiologically switches between two states: an active form bound to GTP and an 
inactive form bound to GDP. NRAS is activated after the binding of extracellular 
subtrates to a specific tyrosine kinase receptor (e.g., c-KIT, ERBB4). NRAS may 
interact with several RAF proteins, which are then phosphorylated and activated. 
Activating mutations in NRAS are identified in around 20% of melanoma cases and 
these mutations act by keeping the NRAS protein under its GTP-bound active form. It 
results in a constitutive activation of both the RAS-RAF-MEK-MAPK and the PI3K-
AKT pathways [29, 36, 43, 44, 45]. 
PI3K-AKT. The first step of the PI3K-AKT pathway consists of the production of 
phosphatidylinositol (3,4,5) triphosphate (PIP3) by the phosphoinositide 3-kinase 
(PI3K). The PIP3 activates the AKT serine/threonine kinase that subsequently 
promotes cell growth and proliferation. The PI3K-AKT pathway is commonly 
activated in melanoma and may result from activating mutations in the NRAS oncogene 
but also from the inactivation of the PTEN tumor suppressor. The latter physiologically 
mediates the dephosphorylation of the PI3K enzyme, acting as a negative regulator of 
all the downstream effectors. PTEN is mutated in 10-30% of melanoma and results in 
constitutive activation of the PI3K pathway in a receptor-independent way. Finally, a 
specific mutation (E17K) in the AKT3 isoform has been identified in melanoma cell 
lines, resulting in constitutive activation of the protein [29, 31, 36, 46, 45]. 
Neurofibromin 1 (NF1). The NF1 gene encodes a tumor suppressor that 
physiologically downregulates both the MAPK and PI3K pathways. It stimulates the 
GTPase activity of NRAS to promote the transition from the active RAS-GTP form to 
the inactive RAS-GDP, acting as a negative regulator of the protein [47]. The 
mutations inducing loss of NF1 function prevent the regulation of NRAS and induce 
its constitutive activation. Mutations in NF1 are mainly found in desmoplastic 
melanoma and in most cases are associated with other mutations, e.g., in BRAF or 
NRAS [48]. 
Tyrosine kinase receptors. ERBB4 is a member of the ERBB/HER family of 
tyrosine kinase receptors. The mutations in ERBB4 increase the kinase activity, 
resulting in an anchorage-independent cell growth and melanoma progression. c-KIT 
is a tyrosine kinase receptor that plays a role in melanocytic development. 
Amplification in c-KIT have been reported in around 6-8% of different subtypes of 
melanoma. The role of c-KIT in melanoma remains unclear but functional analyses 
show that specific mutations in c-KIT may activate the PI3K pathway in normoxic 
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conditions and the RAS-RAF-MEK-ERK-MAPK pathway in hypoxic conditions [45, 
49]. 
 
 
Figure 6: Main signaling pathways upregulated in melanoma. The activation of MAPK pathway 
results from mutation and activation of the proto-oncogenes NRAS or BRAF or mutation and inactivation 
of the tumor suppressor NF1. The activation of the PI3K/AKT pathway results from activating mutation 
in the AKT proto-oncogene or mutation and loss of function of the tumor suppressors PTEN or NF1. 
The upregulation of these two signaling pathways promotes cell growth, proliferation, survival, 
migration, and invasion. Figure adapted from Dralle et al. [50]. 
2.5 Treatment 
 
Currently, only primary melanoma is curable and provides a five-year survival rate 
over 90% [29]. The standard treatment consists of the surgical removal of the primary 
tumor and does not require any additional therapy [29, 32]. In contrary, late-stage 
melanoma is more aggressive. The five-year survival rate is estimated around 5% for 
malignancies that have disseminated to other major organs [51]. A range of therapeutic 
options for the management of patients with melanoma exist and the choice of 
treatment depends on the stage of the tumor at the time of diagnosis [32]. However, 
metastatic melanoma remains difficult to treat, especially due to the development of 
mechanisms of resistance in tumor cells [51]. 
Radiotherapy. The use of radiotherapy in the management of melanoma is limited 
as different subtypes of melanoma are radiotherapy resistant. This resistance is due to 
higher abilities of cancer cells to repare the DNA damages induced after exposure to 
low-dose radiation [32]. Thereby, radiotherapy is only used in a few cases: either as a 
first-line treatment of primary melanoma to replace surgery or as adjuvant therapy after 
tumor removal to prevent cancer recurrence [32, 52]. 
Chemotherapy. Only a few number of chemotherapeutic drugs show anti-tumor 
effects on melanoma including dacarbazine (DTIC), platinum analogs (cisplatin, 
carboplatin), taxanes (docetaxel, paclitaxel), and nitrosureas [53]. The use of these 
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agents in the treatment of metastatic melanoma is limited due to systemic toxic effects 
and the development of multidrug resistance [29, 53]. Moreover, the use of 
chemotherapy as single therapy only shows a low response rate on patients’ survival. 
Attempts have been carried out to combine several chemotherapy regimens to obtain 
better results on the overall survival rate, but no real benefits have been achieved [53]. 
Immunotherapy. Research in the field of immunotherapy has grown very fast 
these past few years. This kind of therapy is particularly promising in the management 
of patients with melanoma because the malignancy is considered as one of the most 
immunogenic malignancies. Many efforts are underway to modulate and boost the 
patient’s immune system by targeting key molecules in the regulation of the immune 
response [32, 54]. 
 
The interferon-α (IFN-α) drug is a mixture of proteins with anti-tumor properties 
such as antiangiogenic, differentiation-inducing, pro-apoptotic, antiproliferative 
effects, etc. [55]. In 1986, the Food and Drug Administration (FDA) approved the use 
of this drug as adjuvant therapy in the treatment of melanoma [32]. However, as IFN-
α seems to be only effective in a subset of patients, there are now many controverses 
about the real benefits to use this drug in the management of melanoma [51, 55]. 
The administration of high dose of interleukin-2 (IL-2) was approved by the FDA 
in 1998 for the management of patients affected with distant metastatic melanoma. IL-
2 works as a stimulator of T-cells function and proliferation. When activated, T-cells 
induce a specific immune response that promotes melanocytes apoptosis [32]. 
However, IL-2 presents high level of toxicity throughout the entire body, limiting the 
use of IL-2 only on patients likely to respond well to the treatment [56]. Clinical trials 
are underway to use alternative cytokines such as IL-15 and IL-21. These cytokines 
act in a similar way than IL-2 but show lower burden of toxicity. 
Since 2011, three immune checkpoint inhibitors (i.e., ipilimumab, pembrolizumab, 
and nivolumab) have been approved by the FDA for the management of unresectable 
or mestastatic melanoma [57]. These drugs have been successfully assessed in clinical 
trials. Treated patients show durable anti-tumor response and an increase in the overall 
survival rate [31]. These checkpoint inhibitors bind and blockade either the cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) (ipilimumab) or the programmed cell 
death 1 protein (PD1) (pembrolizumab and nivolumab). As CTLA-4 and PD1 are 
important negative regulators of T-cells immune function, their inhibition results in 
increased activation of the immune system [32, 58]. 
Targeted therapy. As previously described (Section 2.3), melanoma is widely 
associated with mutations in the BRAF proto-oncogene, and in most cases with the 
BRAFV600E mutant [59]. It has led to the development of small inhibitors designed to 
target the BRAF protein and to prevent the activation of all its downstream effectors 
[32]. Three generations of inhibitors have been developed. The first generation showed 
a lack of specificity for the BRAFV600E mutant, but the improved design of the next 
generations of inhibitors improved the survival rate in many patients. The major failure 
in targeted therapy is that cancer cells become resistant to the inhibitors indecreasing 
their long-term benefit and limiting their use in monotherapy. It is suggested to use a 
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combination of multiple inhibitors (e.g., BRAF and MEK inhibitors) as standard 
targeted therapy in patients with BRAFV600E positive metastatic melanoma [31, 60]. 
2.6 Drug Resistance 
 
During these past 30 years, there has been many advances in the diagnosis and in the 
management of melanoma thanks to the development of targeted therapies. Despite 
these advances, the prognosis of the malignancy remains poor and a lot of patients die 
because of tumor recurrence or dissemination throughout the body [51]. One of the 
major cause is the resistance of cancer cells to a wide range of anti-cancer drugs. This 
resistance may be either intrinsic (i.e., already present before the begining of the 
treatment) or extrinsic (i.e., arriving later during the course of the treatment) [31]. 
Chemotherapy is usually ineffective in the management of melanoma as the 
malignancy is resistant to the majority of chemotherapeutic agents. This 
chemoresistance may result from increased abilities of DNA repair, dysregulation of 
apoptotic pathways, but also from the expression of drug efflux transporters on the 
plasma membrane [51, 61]. These mediate the efflux of drugs out of the cell, reducing 
their intracellular accumulation, and limiting their cytotoxic effect. Melanoma cells 
may express on their plasma membrane many ABC transporters including ABCB1, 
ABCC1, ABCA9, ABCB5, ABCB8, ABCD1, and ABCG2 [61, 62]. Although several 
of these transporters (e.g., ABCB1) are well described as major mediators of 
chemoresistance in different subtypes of cancers, this specific role in melanoma 
remains uncertain [63, 64]. However, a particular interest was given on ABCB5, which 
was shown to be predominantly expressed in pigmented cells. This transporter was 
shown to be a marker of melanoma-initiating cells, and to have a role in melanoma 
drug resistance and melanoma development (Section 3.3).  
The resistance to targeted therapies is another common failure in the treatment 
of melanoma. The intrinsic resistance to targeted therapy may result from already 
existing mutations in other genes than the targeted one. These mutations allow the cells 
to escape to the effect of the inhibitor. In addition, tumor cells may become resistant 
later during the course of the treatment. Palmieri et al. [31] described two distinct 
mechanisms to explain the acquired resistance. The first one, also the main cause of 
resistance to BRAF inhibitors, consists in reactivating the MAPK pathway. It may 
results from MEK-activating mutations, BRAFV600E splicing variants, etc. The second 
mechanism of acquired drug resistance is MAPK-independent and is due to the 
activation of alternative signaling pathways that also control and promote cell 
proliferation [31]. 
3. ABCB5 
 
The ABCB5 transporter is a member of the B family of ABC transporters, 
predominantly expressed in pigmented cells (i.e. melanocytes, testis, and retinal 
pigmented epithelium). The transporter has been shown to be a marker of skin 
progenitor cells, melanoma stem cells, and more recently of limbal stem cells. It is also 
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reported to be a mediator of multidrug resistance in melanoma, colorectal cancer, 
hepatocellular carcinoma, and in several hematological malignancies [65-71]. More 
recently, studies suggest that beyond its role in chemoresistance, ABCB5 could also 
be involved in the tumor development and progression [65, 68, 72-75]. 
3.1 Structure 
 
The ABCB5 gene is located on chromosome 7p21. Studies reveal that at least 11 
transcript variants of ABCB5 exist, among those three have been well documented: 
ABCB5 full-length (FL), ABCB5β, and ABCB5α [76]. 
The ABCB5FL has 28 exons and 1257 amino acids (aa). Kawanobe et al. 
performed analysis of the tissue expression level of the full length isoform. They 
revealed that the ABCB5FL transporter is solely expressed in prostate and testis [21]. 
The topology of ABCB5FL (Figure 7(a)) is described as the conventional structure of 
the majority of all ABC transporters. It consists in two transmembrane domains 
(TMDs), each of them composed of six α-helices, and two nucleotide binding domains 
(NBDs) for the binding and hydrolysis of two ATP molecules [76]. Other studies 
identified additional functional domains that consist of 14 N-glycosylation sites. 
Among these sites, two are located in the extracellular loop of the transporter and may 
play a role for the trafficking of the protein to the plasma membrane [76]. Phylogenetic 
and bioinformatic studies show that the full-length isoform has retained the 
conservative domains common to all ABC transporters throughout the entire 
mammalian evolution, suggesting that the ABCB5 full-length isoform corresponds to 
the functional form of ABCB5 [76]. 
The ABCB5β isoform contains 19 exons and 812 aa. It is predominantly found in 
melanocytes and other types of pigmented cells, and is highly expressed in melanoma. 
The predicted topology of the β isoform (Figure 7(b)) corresponds to a "half-
transporter like" structure which is composed of one TMD flanked by two NBDs. This 
feature is atypical for a half-transporter that normally possesses only one NBD. 
However, one of the two NBD lacks the Walker A motif, preventing the binding of 
one ATP molecule. This property suggests that the half-transporter alone is not 
functional. These data are supported by the presence of dimerization motifs (called 
coil-coiled regions) in the N-terminal region of ABCB5, indicating that the β isoform 
might homo- or heterodimerize to create a functional transporter [21, 76]. Our 
laboratory has just recently demonstrated with the technique of Bioluminescence 
Resonance Energy Transfer (BRET) that ABCB5β may at least heterodimerize with 
the B family members ABCB6 and B9. Finally, Moitra et al. has identified six N-
glycosylation sites. Similarly to those found in ABCB5FL, they could be important for 
the transport of the protein to the plasma membrane. 
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Figure 7: Structural topology of ABCB5FL and ABCB5β (a) Structure of ABCB5 full length: two 
transmembrane domains (TMD), each of them composed of six α-helices, and two nucleotide binding 
domains (NBD) for the binding and hydrolysis of two ATP molecules. (b) Half-transporter like structure 
of ABCB5β isoform: one TMD with six α-helices flanked by two NBDs instead of one as it would be 
expected for a conventional half-transporter. Figure adapted from Gillet et al. [5]. 
The ABCB5α form is a small soluble protein of 131 aa. This isoform has an 
expression profile similar to the β isoform both in normal and cancerous cells. 
Although the studies on this protein are sparse, it seems that it acts as a regulator rather 
than an efflux transporter [21, 76]. 
3.2 Role in cancers 
 
As mentioned above, ABCB5 is overexpressed in a number of cancers such as 
melanoma, breast cancer, colorectal cancer, hepatocellular carcinoma, and several 
hematological malignancies [76]. To date, ABCB5 has been characterized as a gene 
mediating multidrug resistance in human melanoma, hepatocellular carcinoma, and 
colorectal cancer (CRC) [68]. In these cancers, the transporter is preferentially 
expressed by a subpopulation of CD133+ cancer stem cells which show resistance to 
the majority of chemotherapy regimen (e.g., 5-fluorouracil in CRC). ABCB5 also 
serves as biomarker of this cancer stem cells population and is an indicator of tumor 
recurrence and poor survival [68]. Beyond the implication of ABCB5 in MDR, there 
is a growing body of evidence that support a role of the transporter in tumorigenesis, 
independent from its function as drug efflux transporter [6]. In 2011, Wilson et al. 
identified a drug efflux independent role of ABCB5 in CRC, promoting more efficient 
tumor growth and progression [68]. This role in CRC tumorigenesis was further 
investigated in 2018 by Guo et al.. They studied the effects of either the knockdown 
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of ABCB5 gene expression or the inhibition of transporter activity on tumor 
progression. The results show that tumor progression decreases when ABCB5 
expression is downregulated and when the transporter activity is blocked, compared to 
the ABCB5 wild-type condition. They suggest that the transporter partly controls cell 
invasion, but the full mechanism remains unclear. 
3.3 Role in melanoma 
 
The interest to study ABCB5 has grown these past few years as it is amongst the most 
frequently mutated gene in melanoma [77, 78]. The role of ABCB5 in the mechanism 
of melanoma multidrug resistance is relatively well understood but its role in tumor 
development and progression is unclear and controversial. First reports describe that 
ABCB5 promotes tumor progression, invasion, and metastases [74]. However, more 
recent analyses performed by Sana et al. suggest that ABCB5 acts as a tumor 
suppressor and prevents tumor initiation through the inhibition of cell proliferation 
[78]. 
3.3.1 Multidrug resistance 
ABCB5 preferentially marks a subpopulation of CD133+ malignant melanoma-
initiating cells (MMICs). These cells present a stem cell phenotype: unlimited self-
renewal capacity, tumor-propagating abilities, but also multidrug resistance. For the 
latter, MMICs have shown to be insensitive and resistant to a range of anticancer drugs 
such as camptothecin, doxorubicin, paclitaxel, docetaxel, etc. There is a strong body 
of evidence of an involvment of ABCB5 in this mechanism of multidrug resistance by 
the efflux of these drugs out of the cell [74]. This role is supported by additional studies 
performed by Huang et al. who showed that the inhibition of ABCB5 through small 
interference RNA (siRNA) increases the cancer cells sensitivity to camptothecin [79]. 
3.3.2 Tumorigenesis 
A role of ABCB5 in promoting tumor growth, progression, and metastases has been 
described in malignant melanoma-initiating cells (MMICS). Wang et al. performed in 
vitro experiments on ABCB5+ MMICs and on ABCB5− melanoma cells and their 
results showed higher cell migration and invasion in the ABCB5+ population compared 
to the ABCB5− one. The data are supported by the reduction of these metastatic 
properties when ABCB5 is knowdown in MMICs. It is assumed that this role is due to 
an activation of the NF-κB pathway that subsequently exerts pro-tumorigenic effects. 
The activation of the NF-κB requires several molecules, e.g., the p65 protein. It 
appears that ABCB5 promotes the stability of the p65 protein through the inhibition 
of its ubiquitination and degradation, contributing to the activation of the NF-κB 
pathway. Another study performed by Wilson et al. revealed an additional ABCB5-
regulated signaling pathway in MMICs. They identified that ABCB5 controls the 
secretion of IL-1β that serves: (i) to maintain the undifferenciated phenotype of 
MMIC; (ii) to promote tumor growth through an IL-1β-IL8-CXCR1 cytokine 
signaling circuit [73]. 
Melanomagenesis results from either mutations activating an oncogene and 
inactivating a tumor suppressor or from mutations simultaneously inactivating two 
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tumor suppressors. Analyses of melanoma samples with mutations in ABCB5 show in 
75% of cases additional mutations in NRAS (an oncogene) and in 62.5% of cases 
mutations in CDKN2a (a tumor suppressor gene), suggesting that ABCB5 is a tumor 
suppressor. Sana et al. [78] recently carried out in vitro analyses to study the 
deleterious effect of mutations inactivating ABCB5 on the cell phenotype. The 
experiments were performed on the 17T and 63T human melanoma cells obtained from 
patients samples and which both carry activating mutation in the NRAS oncogene. In 
addition, the 63T cell line also harbors mutations in the PTEN and CDKN2a tumor 
suppressors. They have produced different clones from these two cell lines to stably 
overexpress either ABCB5 wild-type or ABCB5 with loss-of-function mutations. 
Afterwards, a series of tests were perfomed to assess: cell proliferation, anchorage 
independent growth, and migration abilities. The results have shown for the cells 
mutated for ABCB5 higher rate of proliferation, an increase in the number of colonies 
after the anchorage independent growth assay, and increased migration. Taken 
together, these data suggest that loss-of-function mutations in ABCB5 accelerate the 
development of melanoma. To data, in vivo experiments on mice models are underway 
to transpose the results observed in vitro [78]. 
3.4 Characterization 
 
Despite a strong body of evidence of a role of ABCB5 in cancer MDR, the transporter 
remains little characterized. Little is known about its subcellular localization, its 
substrates, and its physiological function. Moreover, its role in tumorigenesis remains 
controversial. 
Gene knockout cell lines constitute a powerful strategy to study gene function 
through the loss-of-function phenotype. To date, three types of nucleases have been 
engineered to introduce site-specific DNA double-strand breaks (DSBs). In absence of 
a specific template donor, the cell repairs DNA by a mechanism of non-homologous 
end-joining DNA (NHEJ) repair. This mechanism leads to the apparition of small 
deletions or insertions (called indels) that frequently induce frameshift mutations and 
the apparition of premature stop codon. The zinc finger (ZF) and transcription 
activator-like effectors (TALEs) are the first nucleases developed. These proteins 
consist of DNA-binding domains that individually recognize either 3 (ZF) or 1 
(TALEs) bp of DNA. The modulation and the assembling of several domains allow to 
target specific DNA sequences. Both ZF and TALEs can be coupled with the FokI 
nuclease that subsequently induce DSBs cleavage in DNA. These two strategies 
present some limitations, mainly due to their context-dependent specificity. In 
addition, the construction of TALEs complexes is time-consuming and costly [80]. 
The Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 
has been developed more recently and is now widely used as powerful genome editing 
tool (Figure 8). The method is based on a complex formed by a guide RNA (gRNA) 
and a Cas9 endonuclease that can induce a double-strand break cleavage in a specific 
DNA region. The gRNA contains a RNA scaffold and a 20-nucleotide sequence 
complementary to the targeted loci. One of the few requirements of the gRNA is that 
the 3’-end of the targeted DNA region must directly be followed by a protospacer 
adjacent motif (PAM). It is essential for the binding of Cas9 to DNA. The PAM 
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sequence is specific to the Cas9 species, and the most commonly used in genome 
engineering is the Streptococcus pyogenes (S. pyogenes) Cas9 enzyme, which 
recognizes the 5’-NGG PAM motif. After DNA binding, Cas9 induces a double-strand 
break DNA cleavage three nucleotides upstream the PAM sequence, i.e. between the 
17th and 18th nucleotide of the gRNA. Following the DNA cleavage, two scenarios 
may be considered. Firstly, in presence of a template donor, the cell repairs DNA by a 
mechanism of homology directed repair (HDR). The result consists of a gene 
correction or replacement depending on the template donor. Secondly, if non donor 
sequence is provided, the DNA cleavage is followed by a mechanism of NEJH DNA 
repair that leads to the deletion of several nucleotides, which in many case induces 
frameshift mutations [81, 82, 83]. 
 
 
Figure 8: Overview of the CRISPR/Cas9 method. The guide RNA (gRNA) is composed of a scaffold 
and a 20-nucleotide sequence complementary to the targeted DNA region. The Cas9 enzyme is bound 
to the gRNA. The recruitment and binding of the gRNA/Cas9 complex to the targeted DNA region is 
directly followed by a protospacer-adjacent motif (PAM). The Cas9 endonuclease induces a double-
strand break DNA cleavage. Two scenarios may be considered: (i) small nucleotide deletions resulting 
in frameshift mutations, (ii) a homology directed repair (HDR) in presence of a template donor, leading 
to gene replacement or correction. Figure adapted from Macrogen Humanizing Genome (available at: 
http://www.macrogen.com). 
The CRISPR/Cas9 technique has several advantages over ZF and TALEs: unlike the 
ZF and TALEs strategies that recognize sequences by a protein-DNA interaction, the 
CRISPR/Cas9 directly targets genomic DNA regions with a specific gRNA. These gRNA 
are easily synthetized, highly specific, and they may be rapidly introduced inside the cell 
compared to the protein domains of both ZF and TALEs. Taking all these advantages, the 
CRISPR/Cas9 is now recognized as the most promising and powerful technique to induce 
genome modifications [84].  
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Objectives 
 
The research project realized for this master thesis can be divided into two main parts. 
The first one is the creation of ABCB5-knockout human melanoma cell lines with the 
CRISPR/Cas9 tool. The second aims at better characterizing ABCB5 through the study 
of the transporter subcellular localization. 
The generation of the ABCB5-knockout human melanoma cell lines will be 
performed on the Mel-Juso unpigmented primary melanoma cells with the 
CRISPR/Cas9 genome editing tool. The purpose is to remove a large fragment of the 
gene to prevent the expression of both the ABCB5 full-length and β isoforms. Three 
different RNA guides will be designed to target specific exons of the ABCB5 gene in 
order to remove either a fragment of 53 kb or 125 kb. The proper deletion will be 
validated at the genomic level by screening PCR followed by sequencing, and the 
inhibition of protein synthesis will be assessed by Western Blot. In addition, the latter 
will prove and validate the specificity of the anti-ABCB5 antibodies used. The purpose 
of these ABCB5-knockout cell lines is to create a powerful tool to pursue the 
characterization of the ABCB5 transporter. 
The study of ABCB5 subcellular localization will be performed by subcellular 
fractionation following the method described by de Duve et al. [85]. A first set of data 
from previous cell fractionation carried out by Sana et al. suggests a mixed localization 
of ABCB5 in the nuclear and microsomal fractions. However, these data have not been 
validated yet, mainly due to the lack of specificity of the antibodies used for the 
detection of ABCB5. If the ABCB5-knockout cell line confirms the specificity of these 
antibodies (i.e., by the Western Blot mentioned above) a possible future work would 
be to perform a subcellular fractionation simultenaeously on both ABCB5-expressing 
and ABCB5-knockout Mel-Juso cell lines to get robust data about the transporter 
localization.  
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Materials and Methods 
 
1. Choice of the model 
1.1 Cell line and culture conditions 
 
Human Mel-Juso unpigmented primary melanoma cells were used to generate the 
ABCB5 knockout (KO) cell line and to study the subcellular localization of the 
transporter. Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, 
Lonza, Belgium) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS, 
GE Healthcare Life Sciences, USA) and 0.1% of Pen/Strep (Gibco, Carlsbad, USA) 
under 5% CO2 at 37
◦C. 
1.2 ABCB5 constitutive expression 
 
The constitutive expression of ABCB5 in ABCB5-expressing Mel-Juso cells was 
assessed and confirmed by reverse transcription followed by real-time PCR (RT-
qPCR). 
RNA extraction. Cells were first trypsinized and centrifuged at 1,200 rpm (Rottina 
380 R, Hettich, Germany). 1 mL of Trizol (Fisher Scientific, Hampton, USA) was 
added and the cell lysate was conserved at -80◦C. The following day, the lysate was 
thawed and 200 µL of chloroform was added (Fisher Scientific, Hampton, USA), 
before incubation for 5 min at room temperature (RT). Then, the tube was centrifuged 
at 12,000 g (Sigma 1-16K, Germany) for 15 min at 4◦C, and the aqueous phase was 
recovered. Afterwards, the RNA was purified using the RNeasy Mini Kit of Qiagen 
(Hilden, Germany), following the instructions of the manufacturer. Finally, the RNA 
was quantified by spectrophotometry (Spectramax I3, Molecular Devices, Sunnyval, 
USA). 
Reverse Transcription. cDNA’s were synthesized from total RNA using the 
HighCapacity cDNA Reverse Transcription Kit (Thermo Fischer Scientific, Waltham, 
USA) and following the instructions of the manufacturer. The samples were conserved 
at 4◦C before performing the qPCR. 
Real Time PCR. The TaqMan qPCR reaction mixture was prepared in a total 
volume of 20 µL and contained: 10 µL of TaqMan Universal Master Mix (Thermo 
Fischer Scientific, USA), 1 µL of TaqMan probe (Life Technologies, Belgium), 8 µL 
of H2O, and 1 µL of MelJuso cDNA. Different TaqMan probes were used to target 
four regions of the ABCB5 cDNA and one probe for the 18s cDNA. 18s was used as 
the housekeeping gene in the qPCR analyses as its expression is stable in Mel-Juso 
cell line. Samples were loaded on a 96-well plate (HardShellPCR plates 96-well, Bio-
Rad laboratories, USA), and run on the qPCR machine (CFX96 TouchTM Real-Time 
PCR Detection System, Bio-Rad, USA). The thermal cycle conditions were as follows: 
2 min at 50◦C and 10 min at 95◦C followed by 39 cycles at 95◦C for 15 s and 60◦C for 
1 min. Results were then analysed with the CFX ManagerTM Software (Bio-Rad, USA). 
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1.3 Transfection assay 
 
Mel-Juso cells were transfected with TurboGFP plasmid (431 ng/mL), using either 
Lipofectamine 2000 (Invitrogen, Life Technologies, Belgium) or JetPrimeTM (Polyplus 
transfection, France). The purpose was to assess and choose the most efficient method 
of transfection. The day before transfection, cells were seeded at a density of 25 ×103 
cells/well in a 12-well plate and in 1 mL of complete growth medium (DMEM, 10% 
FBS, 0.1% Pen/Strep), to achieve 60-70% confluence the next day. 
JetPrime. The mix for transfection was prepared following the protocol and the 
standard conditions (i.e., 1:2 DNA to JetPrime ratio (w/v)) given by the manufacturer: 
TurboGFP plasmid (0.8 µg; 1.2 µg or 1.5 µg), JetPrime buffer, and JetPrime reagent. 
Then, 75 µL of the mix was added to each well and the plate incubated at 37◦C for 48 
h. Results were analyzed by flow cytometry (BD FACSVerseTM, Biosciences, USA). 
Lipofectamine 2000. The cell medium was removed 2 h before transfection and 
replaced by medium without Pen/Strep (DMEM, 10% FBS), at a volume of 500 µL 
per well. In one mix, the appropriate amount of DNA plasmid (1 µg; 1.6 µg; 2 µg or 
2.5 µg) was diluted in 50 µL of Opti-MEM Reduced Serum Medium (Gibco, Life 
Technologies, Belgium). In a second mix, 50 µL of Lipofectamine 2000 Reagent were 
diluted in 250 µL of Opti-MEM Medium, and the mix was incubated for 20 min at RT. 
Then, 50 µL of diluted Lipofectamine 2000 Reagent were added to diluted DNA (1:1 
ratio). The DNA-lipid complex was applied to the cells, and the plate incubated at 37◦C 
for 48 h before analyzing the results by flow cytometry (BD FACSVerseTM, 
Biosciences, USA). 
Flow cytometry. After 48 h of incubation, cells were prepared for flow cytometry. 
The medium was removed and the cells were washed with 1 mL of PBS (DPBS, Lonza, 
Verviers, Belgium). Then, the cells were trypsinized with 200 µL of trypsin. 1 mL of 
medium (DMEM, 10% FBS, 0.1 % Pen/Strep) was added and the cell suspension 
transferred in a 15 mL tube. The tube was centrifuged at 300 g for 5 min (Rottina 380 
R, Hettich, Germany) and the pellet was resuspended in 800 µL of PBS (DPBS, Lonza, 
Verviers, Belgium)/BSA (Carl Roth, Germany) 1%. The tube was centrifuged at 300 
g for 5 min and finally resuspended in 400 µL of PBS/BSA 1%. Then, the cells were 
run on a BD FACSVerseTM flow cytometer (BD Biosciences, USA) and excited with 
the 488 nm laser line. 10,000 events were evaluated per sample. Analysis and 
calculation of the transfection efficiency were performed with the BD FACSuite 
software. 
2. CRISPR/Cas9 
2.1 Design of guide RNAs 
 
Three guide RNAs (gRNAs) were designed to target exons 4 (150 bp), 15 (161 bp), 
and 27 (146 bp) of the full-length (FL) isoform of human ABCB5 gene 
(NM001163941.1, NCBI Reference Sequence). The online-tool “Optimized CRISPR 
Design” from Zhang’s laboratory (http://crispr.mit.edu) was used to determine and 
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classify the gRNAs available at the targeted loci and the best gRNAs were chosen to 
maximize on-target specificity (score (%)) and minimize the number of off-target sites 
(total off-targets and genic off-targets) (Table 1). 
 
Name Target Sequence (5’ - 3’) Total Genic Score 
   off-
targets 
off-
targets 
(%) 
4 Exon 4 GGACTAGACATCCACTAATA 74 2 86 
15 Exon 15 GCAAAGGTCGGACTACAATCG 22 2 96 
27 Exon 27 GTCATTATCGAGGGCTGAAG 85 3 82 
Table 1: gRNAs designed to target specific exons in ABCB5 by the CRISPR/Cas9 system. 
2.2 Sequencing of ABCB5 targeted exons 
 
Exons 4, 15, and 27 of the ABCB5 gene in Mel-Juso cell line were amplified by PCR 
and sequenced to assess the presence of single-nucleotide polymorphisms (SNPs) at 
the region targeted by the gRNA. 
Genomic DNA extraction and quantification. DNA was extracted from Mel-
Juso cell line. The culture medium (DMEM, 10% FBS, 0.1% Pen/Strep) was removed 
and cells washed with Dulbecco’s Phosphate Buffered Saline (DPBS, Lonza, Verviers, 
Belgium). Cell suspension was centrifuged at 12,000 rpm for 10 min (Rottina 380 R, 
Hettich, Germany). The supernatant was removed and 200 µL of lysis buffer 1X (10 
mM Tris-HCl pH 8, 50 mM KCl, and 0.1% Tween 20) added to the pellet. Tube was 
incubated at 95◦C during 5 min, before adding 5 µL of proteinase K (Promega, 
Madison, WI, USA). The tube was incubated at 55◦C for 30 min and afterwards 
centrifuged at 15,000 g for 2 min (Sigma 1-16K, Germany). The supernatant was 
recovered and 200 µL of isopropanol were added to precipitate DNA. Centrifugation 
was performed at 15,000 g for 2 min, before removing isopropanol. Then, 200 µL of 
ethanol 70% were added to the pellet. The tube was centrifuged at 15,000 g for 2 min, 
and the ethanol removed. The tube was dried for 15 min at RT. The pellet was 
suspended in 30 µL H2O, before incubation at 65
◦C for 1 h, and under agitation. DNA 
was quantified using spectrophotometer (Spectramax I3, Molecular Devices, 
Sunnyval, USA). DNA was conserved at – 20◦C before amplification by PCR. 
DNA amplification. The PCR primers used are listed in Table 2. Each PCR 
reaction Mix was prepared in a final volume of 50 µL and contained: 25 µL of ready-
to-use DreamTaq Green PCR Master Mix (2X) (ThermoFisher Scientific, Belgium), 5 
µL of primer forward (10 µM), 5 µL of primer reverse (10 µM), 12.5 µL of H2O, and 
2.5 µL of DNA. PCRs were run using the following steps: initial denaturation step at 
95◦C for three min, and 35 cycles of 95◦C denaturation temperature for 1 min, 
annealing temperature ranging from 56◦C to 60◦C depending on the primers for 1 min 
and 1 min of extension at 72◦C followed by another 5 min of final extension at 72◦C. 
PCR products were conserved at 4◦C. PCR products were visualized in 1% agarose 
(Carl Roth, Germany) gel stained with ethidium bromide, after electrophoresis in a 1X 
TAE buffer at 100 V for 30 min. DNA ladder of 100 bp (Thermo Scientific, Belgium) 
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was used as size standard. Non-purified PCR products were sent for sequencing at 
Genewiz. Reverse PCR primers were used for the sequencing. 
 
Target Primer Sequence (5’ - 3’) Tm (◦C) Ta (◦C) 
Exon 4 F TTTTACAGTTGTGGTGCTACG 64 59 
 R GCCTTGCTAGCTTAACGTTTGT 64  
Exon 15 F GAGCAAAGGTCGGACTACAATC 66 60 
 R CTCTGAAACGTTAAACCCTGCT 64  
Exon 27 F GCTTTCTTAATTGCATGCTCCT 62 56 
 R27 ATTCTTTCCAGGCCTTTGTTTT 60  
Table 2: List of primers used for PCR amplification of ABCB5 gRNA/Cas9 targeted exons 
2.3 Construction of the eSpCas9 plasmid 
 
Each gRNA was cloned into an eSpCas9 plasmid from Feng Zhang’s laboratory 
(#71814, Addgene, USA). The plasmid contains the S. pyogenes Cas9 enzyme under 
the control of the CBh promoter. The plasmid allows to clone each gRNA thanks to 
the presence of two BbsI restriction sites and allows to express these gRNAs by the 
U6 promoter. The oligonucleotides used for the cloning are listed in Table 3. Each of 
them was ordered with the gRNA sequence, a 5’ end BbsI restriction enzyme site (i.e., 
CACC for sense and AAAC for antisense oligos), and a phosphorylated 5’ end to 
facilitate the ligation. 
 
gRNA Sense oligo (5’-3’) Antisense oligo (5’-3’) 
4 CACCGGACTAGACATCCACTAATA AAACTATTAGTGGATGTCTAGTCC 
15 CACCGCAAAGGTCGGACTACAATCG AAACCGATTGTAGTCCGACCTTTGC 
27 CACCGCTTCTCACTGTCATTATCGA AAACTCGATAATGACAGTGAGAAGC 
Table 3: Sequences of the oligonucleotides used for the cloning of gRNAs into the eSpCas9 plasmid. 
Cloning. Oligonucleotides were annealed in a final volume of 10 µL containing: 1 
µL of sense and 1 µL of antisense oligonucleotides (100 µM), and 8 µL of H2O. The 
tube was heated at 95◦C (ProvocellTM Esco, Singapore) for 5 min and cold down at RT. 
Finally, annealed oligonucleotides were 200-fold diluted to obtain a final concentration 
of 0.5 µM. 
The eSpCas9 plasmid was digested using the BbsI restriction enzyme (New 
England Biotechnologies, 10,000 U/mL). The mix for the digestion was prepared as 
follows: 10 µg of eSpCas9 plasmid, 10 µL of CutSmart Buffer 10X (New England 
Biotechnologies), 5 µL of BbsI restriction enzyme (New England Biotechnologies, 
10,000 U/mL) and the corresponding volume of nuclease-free water to achieve a final 
volume of 100 µL. The mix was incubated at 37◦C for 1 h (ProvocellTM Esco, 
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Singapore) before inactivating the BbsI enzyme at 65◦C for 20 min. The verification 
of the plasmid digestion was assessed by electrophoresis on an agarose gel 1% with 
ethidium bromide (Carl Roth, Karlsruhe, Germany). Non-digested eSpCas9 plasmid 
was used as control. Both digested and non-digested plasmids were mixed with 6-fold 
diluted loading blue buffer (0,2% Bromophenol blue (p/v), 0,2% xylene cyanole (p/v), 
30% glycerol (v/v) in Tris-EDTA, 6-fold concentrated). Then, the migration was 
performed at 120 V for 25 min before visualization using the Gel Doc XR+ System 
(BioRad, USA). 
The eSpCas9 plasmid was dephosphorylated at the 5’ end to prevent the formation 
of empty plasmid during the step of ligation. The dephosphorylation was performed 
by the addition of 4 µL of the rSAP phosphatase (New England BioLabs, USA) into 
the product of digested plasmid. The mix was incubated at 37◦C before inactivating the 
enzyme at 65◦C for 5 min. 
Each pair of annealed oligonucleotides (0.5 µM) was cloned into a digested and 
dephosphorylated eSpCas9 plasmid. The ligation was performed in a final volume of 
20 µL containing: 1 µL of digested plasmid (100 ng/µL), 2 µL of annealed oligos (0.5 
µM), 1 µL of T4 DNA ligase (New England Biolabs, USA), 2 µL of T4 DNA ligase 
Buffer (New England Biolabs, USA), and 14 µL of H2O. One condition without any 
pair of oligonucleotides was employed as negative control. The ligation was performed 
overnight at 16◦C and then the products of ligation were conserved at -20◦C before 
amplification in E. Coli. 
Amplification. The eSpCas9 plasmids were amplified using the bacterial system 
E. Coli DH5α. The first day, four transformations were performed: three with the 
eSpCas9 plasmid ligated to a pair of annealed oligonucleotides and one empty plasmid 
as negative control. For each condition, 20 ng of plasmid were added to 50 µL of 
competent bacteria. The transformations were carried out by heat shock: 30 min on 
ice, 45 s at 42◦C (ProvocellTM Esco, Singapore) followed by 10 min on ice. Afterwards, 
700 µL of LB (Carl Roth, Karlsruhe, Germany) were added to the mix and the tube 
was incubated at 37◦C for 1 h and under 210 rpm shaking (ProvocellTM Esco, 
Singapore). Then, bacteria were spread on LB (Carl Roth, Karlsruhe, 
Germany)/ampicillin (Sigma-Aldrich, Saint-Louis, USA) agar plates and incubated at 
37◦C overnight. The following day, ten colonies were isolated for each condition. 
The proper ligation of the oligonucleotides into the eSpCas9 plasmid was assessed 
by PCR. PCR primers were chosen in such a way that the amplification is positive only 
if the ligation occured. Reverse primer (5’ TACCGTAAGTTATGTAACGGG) was 
common for all conditions and complementary to a region within the eSpCas9 plasmid. 
Forward primer was specific of the condition and corresponded to the antisense of the 
ligated oligonucleotide (Table 3). The PCR mix was prepared as follows in a final 
volume of 20 µL: 10 µL of DreamTaq Green PCR 2X Master Mix (Thermo Fischer 
Scientific, Waltham, USA), 2 µL of reverse primer (10 µM), 2 µL of forward primer 
(10 µM), 100 ng of plasmid, and the corresponding volume of H2O. PCR amplification 
of 35 cycles (C1000 touch thermal cycler, BioRad, Hercules, USA) was programmed 
with a DNA denaturation for 1 min at 95◦C, primers hybridization during 1 min at 59◦C 
(i.e., annealing temperature, similar for all conditions), and polymerisation by the 
polymerase at 72◦C for 3 min. Then, PCR products were visualized on an agarose gel 
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1% with ethidium bromide (Carl Roth, Karlsruhe, Germany) after a migration at 120 
V for 25 min. For each condition, two positive colonies were selected for the further 
amplification step. 
The selected colonies were placed in 2.5 mL of LB (Carl Roth, Karlsruhe, 
Germany)/ ampicillin (Sigma-Aldrich, Saint-Louis, USA). Amplification was 
performed overnight at 37◦C and under 210 rpm shaking (New Brunswick Innova 
4000). 
Purification. The next day, plasmids were purified using the kit PureYieldTM 
Plasmid MiniPrep System (Promega, Madison, USA) and following the instructions 
given by the manufacturer. Expression plasmids were quantified using a 
spectrophotometer (Spectramax I3, Molecular Devices, Sunnyval, USA) and stored at 
-20◦C until utilization for cell transfection. 
2.4 Transfection 
 
Mel-Juso cells were transfected with three plasmids: two eSpCas9 plasmids cloned 
with the gRNAs of the tested conditions and one pTRIPZ plasmid containing the 
puromycin gene resistance, to serve as selection marker of transfected cells. 
The day before transfection, cells were seeded at a density of 25 ×103 cells/well in 
a 12-well plate and in 1 mL of complete growth medium (DMEM, 10% FBS, 0.1% 
Pen/Strep), to achieve 60-70% confluence the next day. Cells were transfected using 
JetPrimeTM (Polyplus transfection, France) reagent. The mix for transfection was 
prepared following the protocol and the standard conditions (i.e., 1:2 DNA to JetPrime 
ratio (w/v)) given by the manufacturer: 1 µg of the eSpCas9 and pTRIPZ plasmids 
mix, JetPrime buffer, and JetPrime reagent. Then, 75 µL of the mix was added to each 
well and the plate was incubated at 37◦C for 24 h. Afterwards, the medium was changed 
and 2 µg/mL of puromycin (10 mg/mL, Gibco Life Technologies, China) were added 
for 24 h to select cells resistant to the antibiotic (i.e., cells having incorporated the 
pTRIPZ plasmid). 
 
2.5 Generation of monoclonal cell populations 
 
The generation of monoclonal cell populations positive for either the deletion 53 kb or 
125 kb in ABCB5 was performed by seeding transfected cells in 96-well plates at a 
density of one cell per well. 
Following cell counting (Vi-Cell XR Analyzer, Life Sciences, IN, USA) three 
different solutions were prepared with respectively 30, 50, or 60 cells in a final volume 
of 20 mL growth medium (DMEM, 10% FBS, 0.1 % Pen/Strep). Then, 200 µL from 
each solution were placed per well in 96-well plates to seed on average a density of 
one cell per well. When cell confluence reached 100%, cells were harvested. Two-
third of the cell suspension were used for genomic DNA extraction and screening PCR. 
The rest of cell suspension was conserved at -80◦C after addition of cell freezing 
medium (70% DMEM, 20% DMSO, 10% FBS, 0.1 % Pen/Strep). 
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2.6 Knockout validation by PCR screening 
 
DNA extraction. The culture medium (DMEM, 10% FBS, 0.1% Pen/Strep) was 
removed and cells washed with Dulbecco’s Phosphate Buffered Saline (DPBS, Lonza, 
Verviers, Belgium). Cell suspension was centrifuged at 1,200 rpm for 10 min (Rottina 
380 R, Hettich, Germany). The supernatant was removed and 200 µL of lysis buffer 
1X (10 mM Tris-HCl pH 8, 50 mM KCl, and 0.1% Tween 20) added to the pellet. 
Tube was incubated at 95◦C during 5 min, before adding 5 µL of proteinase K 
(Promega, Madison, WI, USA). The tube was incubated at 55◦C for 30 min and 
afterwards centrifuged at 15,000 g for 2 min (Sigma 1-16K, Germany). The 
supernatant was recovered and 200 µL of isopropanol were added to precipitate DNA. 
Centrifugation was performed at 15,000 g for 2 min, before removing isopropanol. 
Then, 200 µL of ethanol 70% were added to the pellet. The tube was centrifuged at 
15,000 g for 2 min, and ethanol removed. The tube was dried for 15 min at RT. The 
pellet was suspended in 30 µL H2O before incubation at 65
◦C for 1 h, and under 
agitation. DNA was quantified using spectrophotometer (Spectramax I3, Molecular 
Devices, Sunnyval, USA). DNA was conserved at – 20◦C before screening PCR. 
PCR amplification. After DNA extraction, different PCR were carried for each 
condition: the exons targeted by the gRNAs were individually amplified and an 
additional PCR was performed to determine if the 53 kb or 125 kb fragment was 
removed. The PCR primers used are listed in Table 4 and the different PCR performed 
in Table 5. PCR were run using the following protocol: initial denaturation at 95◦C for 
3 min, and 35 cycles of 95◦C denaturation temperature for 1 min, annealing 
temperature depending on the primers (ranging from 53◦C to 59◦C) for 1 min, and 1 
min of extension at 72◦C followed by another 5 min of final extension at 72◦C. PCR 
products were conserved at 4◦C before visualization in 1% agarose (Carl Roth, 
Germany) gel stained with ethidium bromide, after electrophoresis in a 1X TAE buffer 
at 120 V for 30 min. DNA ladder of 100 bp (Thermo Scientific, Belgium) was used as 
size standard. 
 
Target Primer Sequence (5’ - 3’) Tm (◦C) 
Exon 4 F4 TTTTACAGTTGTGGTGCTACG 64 
 R4 GCCTTGCTAGCTTAACGTTTGT 64 
Exon 15 F15 TCTTAAACATGCAAAGGTTGTT 57.4 
 R15 AACGTTAAACCCTGCTGACA 59.7 
Exon 27 F27 GCTTTCTTAATTGCATGCTCCT 62 
 R27 ATTCTTTCCAGGCCTTTGTTTT 60 
Table 4: List of primers used for the screening PCR 
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Amplification Primers Ta Product size 
  (◦C) (bp) 
Exon 4 F4 & R4 59 270 
Exon 15 F15 & R15 53 275 
Exon 27 F27 & R27 56 280 
53 kb deletion (4 and 15) F4 & R15 54.7 318 
125 kb deletion (4 and 27) F4 & R27 59 230 
Table 5: PCRs screening to amplify targeted exons and to detect the deletions. 
3. Subcellular fractionation 
3.1 de Duve’s fractionation 
 
Two days before performing the subcellular fractionation, Mel-Juso cells were seeded 
in 10 petris dishes completed with 7 mL growth medium (DMEM, 10% FBS, 0.1% 
Pen/Strep) to achieve 80% confluence the next day. All steps of fractionation were 
performed on ice. First, cells were washed four times with 4 mL of 0.25 M cold sucrose 
solution. Then, cells of each dish were detached and pooled in a Dounce homogenizer 
in a final volume of 2 mL sucrose solution. Cells were disrupted with six strokes of 
the pestle and the cell homogenate was centrifuged at 1,000 g (Allegra, Beckman 
Coulter, USA) for 9 min 16 sat 4◦C. The supernatant (E1) was decanted and kept on 
ice. The pellet (N) was resuspended and rehomogenized in the Dounce by six strokes 
with the pestle. Afterwards, N was transferred in a tared 15 mL tube and made up to a 
final volume of 2 mL sucrose solution, before centrifugation at 1,000 g (Allegra, 
Beckman Coulter, USA) for 7 min 32 s at 4◦C. The supernatant (E2) was collected and 
combined with E1, both representing the cytoplasmic extract (E). The pellet N was 
resuspended in a final volume of 1 mL sucrose solution, weighted, and kept on ice. 
One aliquot of the cytoplasmic extract E was removed and kept on ice for further 
analysis. Then, the rest of the fraction was further fractionated in a L7-35 
ultracentrifuge (Beckman Coulter, USA) using the TI 50 Rotor. Three particular 
fractions (two mitochondrial (M and L) and one microsomal (P)) were successively 
isolated by sequentially increasing speed of centrifugation. Firstly, E was centrifuged 
at 8,000 rpm at 4◦C for 2 min 24 s. The supernatant (LPS1) was collected and 
transferred into a tared tube of 15 mL. The pellet (M) was resuspended and made up 
to a final volume of 2 mL sucrose solution. Then, the fraction was centrifuged at 8,000 
rpm at 4◦C for 2 min 24 s. The supernatant (LPS2) was collected and combined with 
LPS1 to form LPS. M was resuspended in a final volume of 500 µL sucrose solution, 
weight, and kept on ice. The LPS supernatant was centrifuged at 25,000 rpm for 2 min 
24 s at 4◦C. The supernatant (PS1) was collected and transferred into a tared tube of 
15 mL. The pellet (L) was resuspended and made up in a final volume of 2 mL sucrose 
solution, before centrifugation at 25,000 rpm at 4◦C for 2 min 52 s to wash the fraction. 
The supernatant (PS2) was collected and combined with PS1 to form PS. The pellet L 
was resuspended in a final volume of 500 µL sucrose solution, weighted, and kept on 
ice. Finally, PS was centrifuged at 35,000 rpm for 35 min at 4◦C. The supernatant (S) 
was collected and transferred into a tared 15 mL tube. 1 mL was sampled for future 
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analyses and the rest was thrown. P was resuspended in 500 µL sucrose solution, 
weight, and kept on ice. For each fraction, primary dilutions were calculated by 
dividing the volume of the fraction by the amount of starting material. 
After fractionation, six fractions were collected (E, N, M, L, P, and S). The amount 
of proteins in each of them was determined with the Bradford protein assay (BioRad 
Laboratories, USA) and following the instructions given by the manufacturer. 
3.2 Enzymatic dosages 
 
The activity of five enzymes markers was measured: β-galactosidase (lysosome), 
alkaline α-glucosidase (endoplasmic reticulum), alkaline phosphodiesterase (plasma 
membrane), dipeptidyl peptidase 3 (cytosol), and cytochrome C oxidase 
(mitochondria). 
B-galactosidase. The activity of β-galactosidase was assessed by fluorimetry 
(BioRad, USA). The reaction was performed in duplicate for each fraction. The mix 
for each reaction was prepared in a final volume of 190 µL containing: 2.5 µL of 40 
mM 4-MUβ-galactopyranoside substrate (Sigma-Aldrich, Germany), 25 µL of NaCl 
0.4 M, 50 µL of acetate buffer 0.2 M pH 5, 112 µL H2O, and 0.5 µL of Triton X-100 
20% (Promega, USA). Then 5 µL and 10 µL of each fraction were added in two 
cuvettes, before incubation at 37◦C in a water-bath for 45 min. Afterwards, the reaction 
was stopped by adding 1.2 mL of glycine-NaOH buffer (50 mM, EDTA (Carl Roth, 
Germany) 5 mM, 0.05% Triton, pH 10.5), before reading fluorescence emission at 450 
nm. 
Alkaline α-glucosidase. The activity of the enzyme was assessed by fluorimetry 
(BioRad, USA). The test was performed in duplicate for each fraction. First, 0.676 mg 
of 4-MUα-D-glucopyranoside (Carl Roth, Belgium) substrate were dissolved in 200 
µL of ethanol 50%, at 37◦C. Then, the mix for the reactions was prepared in a final 
volume of 1.5 mL containing: 300 µL of glycine-NaOH buffer (0.5 M, pH 9), 3 µL of 
Triton X-100 20% (Promega, USA), 150 µL of substrate, and 1.05 mL of H2O. 
Afterwards, 90 µL of the mix were added in each cuvette, and 5 µL or 10 µL of the 
corresponding fraction were added, before incubation in a water-bath at 37◦C for 1 h. 
The reaction was stopped by adding 1 mL of glycine-NaOH buffer (0.1 M, pH 10.4) 
before reading fluorescence emission at 450 nm. 
Alkaline phosphodiesterase. The enzymatic activity was assessed by colorimetry. 
The reaction was performed in duplicate for each fraction. First, the mix for all 
reactions was prepared with: 1.75 mg of thymidine 5’-monophosphate p-nitrophenyl 
ester sodium salt substrate (Sigma-Aldrich, Germany), 507 µL of glycine hydroxide 
buffer (0.5 M, pH 9.6), 507 µL of zinc acetate 0.01 M, 30.43 µL of NaOH 1M, and 
1.22 mL of H2O. Then, 115 µL of the mix were added in each cuvette and 5 µL or 10 
µL of the corresponding fraction were added. The reaction was incubated in a water-
bath at 37◦C and for 3 hours. The reaction was stopped by adding 1 mL NaOH 0.1 M 
before reading absorbance at 400 nm with a spectrophotometer Lambda 10 
(PerkinElmer, USA). 
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Dipeptidyl peptidase 3. The activity of the enzyme was measured by fluorimetry 
(BioRad, USA). The reaction was performed in duplicate for each fraction. The mix 
for the reactions was prepared with: 500 µL of Tris-Cl buffer (0.5 M, pH 8), 19.97 µL 
of H-Arg-Arg-7-amido-4-methylcoumarin hydrochloride substrate (25 mM), and 
950.5 µL of H2O. Then, 90 µL of the mix were placed in each cuvette and 5 µL or 10 
µL of the corresponding fraction were added. The reaction was incubated in a water-
bath at 37◦C for 1 hour. Then, the reaction was stopped by adding 1.2 mL glycine (50 
mM, EDTA (Carl Roth, Germany) 5 mM, Triton X-100 0.05%, pH 10.5), before 
reading the fluorescence emission at 460 nm. 
Cytochrome C oxidase. The activity of the cytochrome C oxidase was assessed 
by colorimetry. The methods consists in following the decrease of absorbance at 550 
nm of reduced cytochrome C due to its oxidation by the cytochrome C oxidase. The 
solutions required for the assay were prepared as describe below. One dilution solution 
in a final volume of 100 mL with: 2 mL of Triton X-100 2%, 1 mL EDTA (Carl Roth, 
Germany) (0.1 M, pH 7.4), 0.2 mL of phosphate buffer (0.5 M, pH 7.4), and H2O. Each 
fraction was two-fold diluted in this solution before performing the assay. One mix 
with the substrate was made in a final volume of 25 mL with: 6.55 mg of cytochrome 
C substrate (SigmaAldrich, USA), 1.45 mL of phosphate buffer (0.5 M, pH 7.4), 242.6 
µL of EDTA (Carl Roth, USA) (0.1 M, pH 7.4), and H2O. The enzymatic reaction was 
performed for each fraction in a cuvette containing 1 mL of mix substrate and 50 µL 
of the corresponding two-fold diluted fraction. One cuvette was prepared to obtain 
100% reduced cytochrome C, by adding potassium ferricyanide (Science Company, 
USA) to 1 mL of the substrate mix. One cuvette was prepared to obtain 100% of 
oxidized cytochrome C, by adding dithionite to 1 mL of the substrate mix. Then, the 
analysis was performed by spectrophotometry and with the UV WinLab Software 
(PerkinElmer, USA), following the protocol given by the manufacturer. 
3.3 Western Blot 
 
Western Blot was performed to obtain the distribution profiles of histone H1 (marker 
of the nucleus) and ABCB5. First, 15 µg of each fraction were denaturated at 37 ◦C for 
30 min in 45 µL of loading buffer. The proteins were then loaded in either an 8% 
(ABCB5) or 15% (histone H1) SDS acrylamide gel and migration was performed at 
110 V for 1h45. Then proteins were blotted to a PVDF membrane (BioRad, USA) at 
110 V during 2 h. After blocking the membrane 30 min in a 3% milk PBS 0.1% Tween 
20 solution, the anti-histone H1 (monoclonal mouse (ThermoScientific)) and the anti-
ABCB5 (polyclonal goat (Rockland, 600-401-A77S)) antibodies were 500-fold 
diluted in PBS 0.1% Tween 20 3% milk and incubated with the membrane overnight. 
The followig day, the membranes were washed four times during 5 min in PBS 0.1 % 
Tween 20 before incubation with the appropriate secondary antibody (anti-mouse or 
anti-goat) in a 3000-fold diluted solution of PBS 0.1% and Tween 20 3% milk. After 
four final washing of 5 min with PBS 0.1% Tween 20, the membranes were revealed 
with the Western Lightning Plus-ECL kit (PerkinElmer, Waltham, USA). The bands 
at the expected protein size for histone H1 were quantified using the ImageJ software 
and the distribution profile of the protein was graphically represented.  
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Results and Discussion 
1. Characterization of Mel-Juso cell line 
1.1 ABCB5 constitutive expression 
 
We performed a real-time PCR on the parental Mel-Juso cell line to assess the 
constitutive expression of ABCB5. The four TaqMan probes were chosen to hybridize 
different regions of the ABCB5 gene (Figure 9): the probes 40 and 51 target sequences 
found both in the ABCB5 full-length (FL) and β isoforms and the probes 39 and 41 
only recognize regions of the ABCB5FL isoform. 
 
Figure 9: TaqMan probes hybridization sites on the ABCB5 gene. Top: representation of the ABCB5 
full-length (FL) isoform; bottom: representation of the ABCB5β isoform. Probes 40 and 51 recognize 
common regions of both the ABCB5FL and β isoforms. Probes 39 and 41 only target sites of the 
ABCB5FL. 
The results are shown in Figure 10. Each condition was performed in triplicate and 
the 18S ribosomal RNA was used as positive control. The mean Ct values for the 
different probes targeting ABCB5 are: 39.73 (ABCB5 39), 25.29 (ABCB5 40), 36.50 
(ABCB5 41), and 26.77 (ABCB5 51). The data show lower Ct values for the probes 
targeting both the full-length and β isoforms (i.e., 40 and 51) compared to those only 
hybridizing the ABCB5 full length (i.e., 39 and 41). It indicates that Mel-Juso cells at 
least express the β isoform. However, the real-time PCR does not allow to conclude if 
the cell line also expresses the full-length isoform. The mean Ct values for probes 39 
and 41 are higher than 30, and beyond this value, results are often considered as false 
positive that may result: either from primers dimers formation or from a non-specific 
amplification. Although other techniques exist to detect and analyze the abundance of 
specific mRNA (e.g., Nothern Blot, nuclease protection assays, in situ hybridization, 
etc.), the real-time PCR remains the most sensitive method. It is likely that the Mel-
Juso cells do not express the full-length isoform at all. 
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Figure 10: Analysis of ABCB5 constitutive expression in Mel-Juso parental cells. The relative 
fluorescence unit (RFU) is plotted against cycle. The threshold (horizontal line) is set. The five TaqMan 
probes chosen target: 18S ribosomal RNA (positive control), both ABCB5 full-length and β isoforms 
(ABCB5 40 and 51), or only the full-length isoform (ABCB5 39 and 41). The experiment was 
performed in triplicate and the mean Ct values were calculated for each condition. Amplifications run 
with the BD FACSVerse flow cytometer and analyses performed with the BD FACSuite software. 
1.2 Transfection 
 
JetPrime and Lipofectamine 2000 reagents were used to transfect the TurboGFP 
plasmid in parental Mel-Juso cells. The purpose was to determine the most efficient 
method of transfection for the future transfections with the CRISPR/Cas9 system. The 
GFP emission was detected 48 h post-transfection by fluorescence activating cell 
sorting (FACS) and the results were analyzed by the BD FACSuite software (Figure 
11). 
Non-transfected Mel-Juso cells (11(a)) were used to define the thresholds of 
forward scatter (FSC) and side scatter (SSC) parameters to gate cells (P1, orange), and 
to determine the background fluorescence to subtract during the analysis of GFP 
emission by transfected cells (purple). The transfection efficiency (i.e., the percentage 
of cells transfected) was calculated for each condition depending on the transfection 
reagent and the amount of TurboGFP plasmid transfected. 
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(a) 
 
(b) 
 
(c) 
Figure 11: Detection of GFP emission in Mel-Juso parental cells by flow cytometry analysis. (a) 
Non-transfected Mel-Juso (NT) cells used: (i) to set up forward scatter (FSC) and side scatter (SSC) 
parameters to gate cells (P1, orange) (left panel) and (ii) to determine the background fluorescence (right 
panel) to subtract during analysis of GFP emission by transfected cells. (b) Transfection of Mel-Juso 
cells with JetPrime reagent and different amounts of TurboGFP plasmid (0.8 µg; 1.0 µg; 1.2 µg; 1.5 
µg). X-axis: intensity of GFP emission (GFP-A). Background fluorescence (purple) removed from the 
analysis; y-axis: cell size (FSC-A). Analysis performed on gated population (P1, orange). The 
transfection efficiency (%) was measured for each condition by the BD FACSuite software. (c) 
Transfection of Mel-Juso cells with Lipofectamine 2000 reagent and different amounts of Turbo-GFP 
plasmid (1.0 µg; 1.6 µg; 2.0 µg; 2.5 µg). X-axis: intensity of GFP emission (GFP-A). Background 
fluorescence (purple) removed from the analysis; y-axis: cell size (FSC-A). Analysis performed on 
gated population (P1, orange). The transfection efficiency (%) was measured for each condition by the 
BD FACSuite software. 
The results show that the percentage of transfection is on average 52.28% with 
JetPrime reagent (11(b)) and 49.71% with Lipofectamine 2000 (11(c)), indicating that 
both transfection reagents successfully transfect the Mel-Juso cell line. However, it is 
likely that the calculated mean value for JetPrime is underestimated. The low 
percentage (27.16%) of transfection obtained with 0.8 µg of TurboGFP plasmid is not 
consistent with the three other values obtained (higher than 50%). We hypothetize that 
a higher cell confluence in this specific condition before transfection had led to an 
important decrease of the transfection efficiency. However, we should at least 
performed each condition in duplicate to compare the results. 
From these results, we chose the JetPrime reagent for the future transfections with 
the CRISPR/Cas9 system since (i) the reagent has already been successfully used in 
different CRISPR/Cas9 applications, and (ii) because JetPrime presents many 
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advantages over other methods. For instance, the technique requires low amount of 
foreign DNA and transfection reagent to achieve high transfection efficiency. Our data 
support this statement (e.g., an efficiency of 66.88% is achieved after transfection of 
1.5 µg of TurboGFP). Other studies have analyzed on different cell lines, the 
percentage of GFP-positive cells after transfection either with JetPrime or 
Lipofectamine 2000 (Figure 12). For JetPrime, they used half of the amount of reagent 
and transfected DNA compared to Lipofectamine 2000. The results show that even 
with a lower amount of reagent and DNA, the transfection efficiency is always higher 
with JetPrime, and over than 70% [86, 87]. 
 
 
Figure 12: Percentage of GFP-positive cells after transfection either with JetPrime or 
Lipofectamine 2000. The transfection with JetPrime was performed with half of the amount of 
transfected DNA and reagent compared to Lipofectamine 2000. In all cases the percentage of GFP-
positive cells (i.e., the transfection efficiency) is higher with JetPrime and over 70%. Figure adapted 
from Polypus. 
 
Moreover, JetPrime is particularly suitable for multiple plasmids co-transfection 
[88]. This property is important for our future experiments as we will transfect a panel 
of three plasmids in each tested condition (two eSpCas9 plasmids cloned with a 
specific gRNA and one pTRIPZ plasmid for the selection of transfected cells). 
Finally, JetPrime shows lower cytotoxic effects than Lipofectamine 2000 and 
results in higher cell viability. The delivery of the JetPrime complex to the cell is gentle 
and respects the cell morphology. It is due to the nature of the JetPrime reagent, a 
cationic polymer-based molecule which forms positively charged complexes with 
plasmid DNA. Unlike cationic lipids such as Lipofectamine 2000, the JetPrime 
complex does not destabilize the cell membrane and is captured by the cell via the 
endolysosomal pathway. It is followed by a proton-spong effect that leads to the 
release of plasmid DNA in the cytosol. The proton sponge effect is due to the 
polymeric nature of the JetPrime reagent, which attracts H+ within the lysosome. The 
decrease of the intra-lysosomal pH is compensated by an influx of both Cl− and water, 
which finally leads to the swelling and the disruption of the organelle, and the release 
of DNA [88]. 
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2. CRISPR/Cas9: optimization 
2.1 Design of the gRNAs 
 
We firstly defined the regions to target in the ABCB5 gene. The real-time PCR shows 
that Mel-Juso parental cells at least express the ABCB5 transporter under the β 
isoform, but the results do not allow us to conclude if the cells also express the ABCB5 
full-length isoform. Because the purpose of this project is to generate an ABCB5-
knockout cell line for all isoforms, the best way would be to completely remove the 
gene, i.e., a fragment of 150 kb. In this case, both the mRNA transcription and the 
protein expression would be knock-down. However, it appears that, in mammalian 
cells, the larger is the size of the fragment to remove, the lower is the efficiency of the 
CRISPR/Cas9 tool [89]. 
We have decided to test two conditions: the first one is to remove a fragment of 
125 kb and the second one is to remove a fragment of 53 kb in the ABCB5 gene. For 
that purpose, we have selected three exons to target ABCB5: exons 4, 15, and 27. The 
choice of exons 4 and 15 is based on the beginning of the coding regions of either the 
ABCB5 full-length or the β isoform, respectively. Depending on the condition, Mel-
Juso cells will be co-transfected with two gRNAs targeting either exons 4 and 15 (to 
remove 53 kb) or exons 4 and 27 (to remove 125 kb). In both conditions, we expect to 
inhibit the ABCB5 protein synthesis. However, it is likely that only the 125 kb deletion 
will also prevent the mRNA transcription. 
We designed and selected three gRNAs with the "Optimized CRISPR Design" 
software from Zhang’s laboratory (available at: http://crispr.mit.edu/) (Table 6). The 
choice of the gRNAs was based on three important criteria: the number of total off-
targets, the number of genic off-targets, and a specificity score. The number of total 
off-targets consists of possible hybridization of the gRNA with another coding or non-
coding genomic sequence. The number of genic off-targets is more precise and 
represents the binding of the gRNA followed by the Cas9 cleavage in other exons than 
the targeted one. Finally, the software provides a score corresponding to the specificity 
of the gRNA for its target and is quality indicator of the gRNA [90]. The number of 
genic off-targets is one of the most important criteria and this number needs to be as 
low as possible. Indeed, gene disruption can have consequences on its transcription, 
on protein production, and can modify the cell phenotype. We observe that all gRNAs 
show maximum three genic off-targets, which is considered as very low. 
 
Name Target Sequence (5’ - 3’) Total Genic Score 
   off-
targets 
off-
targets 
(%) 
4 Exon 4 GGACTAGACATCCACTAATA 74 2 86 
15 Exon 15 GCAAAGGTCGGACTACAATCG 22 2 96 
27 Exon 27 GTCATTATCGAGGGCTGAAG 85 3 82 
Table 6: gRNAs designed to target specific exons in ABCB5 by the CRISPR/Cas9 system. 
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2.2 Genic off-targets analysis 
 
We performed further analysis of these potential genic off-targets with the "Optimized 
CRISPR design" software to identify: the sequence of the off-target, the chromosome 
location, the number of mismatches between the sequence of the off-target and the 
gRNA, and a score depending on mismatch tolerance. The latter mainly depends on 
two criteria: the mismatches localized between the 8th and the 14th nucleotide at the 3’ 
end of the gRNA are less tolerated than those present at the 5’ end; more than three 
mismatches are not tolerated and usually inhibit the off-target effect. The results show 
for all potential genic off-targets a number of mismatches higher than three and a very 
low tolerance score, meaning that the mismatches present in the off-target sequences 
are not well tolerated by the gRNA (Table 7). Thereby, the probability of gRNA 
hybridization and mutagenesis seems very low. However, it is important to be aware 
of the existence of these off-targets, e.g., for future studies of the ABCB5 gene function 
in which changes in the cell phenotype are expected. In this specific case, off-target 
effects may be a source of bias and may interfere with the results. 
 
gRNA Genic off-target sequence (5’ - 3’) Site Mismatches 
number 
Score 
4 GGAATAGAAATCCAATAAAA chr. 12 4 [4:9:15:19] 0.1 
 GGAATAGAAATGCTCTAATA chr. 6 4 [4:9:12:14] 0.1 
15 CAAAGGTCAGCCCACAATCA chr. 3 4 [9:11:13:20] 0.1 
 CAAAGGTCAGCCTTCAATCC chr. 15 4 [9:11:14:20] 0.0 
27 GACATTTTCCAGAGCTGAAG chr. 16 4 [2:7:10:13] 0.4 
 GGCATTATGGAGGGCTGGAA chr. 15 4 [2:9:18:20] 0.1 
 GTCAGTACCGAGACCTGAAG chr. 4 4 [5:8:13:14] 0.1 
Table 7: Analysis of the potential genic off-targets 
We identified and analyzed the function of the seven genes found within these off-
targets regions (Table 7). Most of them (STYK1, ORC3, KNL1, RHOV, and EGF) work 
as regulators of cell division, proliferation, and differentiation. GPDL1 has an 
independent role specific to cardiac cells. Consequently, the gene is probably not 
expressed by melanoma cells. Finally, the function of VATL1 is unclear and there is 
currently no validated data about it. Identifying the function of the proteins coded by 
these off-targets genes provides first insights about potential modifications that we 
could observe in the cell phenotype. We speculate that if mutation occurs in one of 
these genes, consequences could be, e.g., a slow-down in cell proliferation, a decrease 
in cell viability, or a modification of cell morphology. Although the probability of off-
target mutagenesis seems low, it would be relevant to sequence these seven genomic 
DNA regions to assess and confirm that the genes are not mutated. This kind of 
analysis is particularly important before performing functional studies on the ABCB5 
gene, as off-target effects may confound the interpretation of biological phenotypes 
observed [91]. Moreover, Zhang et al. show that off-target effects are also cell-type 
specific and depend on the integrity of the DNA repair pathways in this cell type [92]. 
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gRNA Genic 
offtarget 
site 
Corresponding gene Gene function 
4 chr. 12 Serine/Threonine kinase 1 (STYK1) Cell proliferation, 
differentiation, and survival. 
 chr. 6 Origin recognition complex subunit 
3 (ORC3) 
Initiation of DNA replication 
15 chr. 13 Glycerol-3-phosphate deshydrogenase 1 
like (GPDL1) 
Cardiac sodium current 
regulation. 
 chr. 15 Kinetochore scaffold 1 (KNL1) Creation of kinetochore 
microtubule attachments and 
chromosome segregation. 
27 chr. 16 Vesicle amine transport 1 like 
(VAT1L) 
Unknown. 
 chr. 15 Ras homology family member V 
(RHOV) 
Control of the actin 
cytoskeleton. 
 chr. 4 Epidermal growth factor transcript 
variant 3 (EGF) 
Cell growth, proliferation, and 
differentiation 
Table 8: Identification and function of genes linked to the potential genic off-targets sites. 
Finally, we must be aware that algorithm-based off-targets prediction presents 
some limitations. The CRISPR MIT software that we used only provides off-target 
sequences which are closely related to the on-target site, e.g., it fails to predict some 
off-targets with less similarity. Other methods exist to provide a genome-wide 
detection of off-target effects (e.g., GUIDE-seq, BLESS, Digenome-seq, etc). 
However, all these techniques are most of the time performed when the CRISPR/Cas9 
system is used for clinical application. In this specific case, safety is a major concern 
and a genome-wide coverage of all potential off-target effects is crucial to ensure that 
no mutation occurred. For the use of the CRISPR/Cas9 in basic research, Tsai et al. 
recommend to perform different types of control experiments that allow to rule out 
potential off-target effects [91]. One possibility is to assess if the initial phenotype 
(e.g., with a constitutive expression of ABCB5 in our specific case) is rescued in the 
ABCB5-knockout cell line after genetic complementation. 
 
2.3 eSpCas9 plasmids construction 
 
We used the eSpCas9 plasmid as expression vector to clone each gRNA. The plasmids 
were digested with the BbsI restriction enzyme before the ligation with a specific 
gRNA. The verification of the proper insertion of the gRNA was performed by PCR, 
followed by sequencing. For each PCR, the reverse PCR primer recognized a common 
sequence within the eSpCas9 plasmid. However, we chose the antisense 
oligonucleotide of the inserted gRNA as forward PCR primer in such a way that the 
PCR is positive only if the gRNA was properly cloned within the eSpCas9 plasmid. 
The results show a band at the expected size of 200 bp for all the three PCRs (Figure 
13). Moreover, the sequencing of each PCR product (Figure 14) confirms that the 
amplified sequence perfectly matches with the corresponding gRNA antisense 
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oligonucleotide, i.e., none mutation occurred during the cloning process. This 
verification by sequencing was particularly important as the sequence of the gRNA is 
short, i.e. 20 nucleotides. A mutation in one nucleotide would be sufficient to prevent 
the hybridization of the gRNA to the site of interest but also to increase the number of 
potential off-target sites. 
 
 
Figure 13: Gel electrophoresis of PCR products using primers for the verification of the proper 
insertion of the gRNAs into the eSpCas9 plasmid. Ladder (L) 100 bp. Negative control (H2O). gRNA 
targeting exon 4 (4), 15 (15), or 27 (27) of ABCB5. The three PCRs are positive, indicating a proper 
insertion of the gRNA within the eSpCas9 plasmid (200 bp). 
 
Figure 14: Sequencing of the PCR products to verify the sequence of each gRNA. None mutation 
was inserted in the gRNA sequence during the step of cloning, as shown by the results of the sequencing: 
each sequence corresponds to the antisense oligonucleotide (5’ - 3’) of the gRNA of interest. From the 
top to the bottom: antisense oligonucleotide from the gRNA targeting exon 4, 15, and 27. The BbsI 
restriction enzyme sites (AAAC) have not been included in the sequences presented here. 
3. ABCB5-knockout: genomic validation 
 
After transfecting cells with the CRISPR/Cas9 system and after selecting these cells 
with puromycin, we have performed the ABCB5-knockout validation. The validation 
of a gene-knockout cell line may be performed at three levels: genomic (by screening 
PCR and sequencing), proteic (by Western Blot), and transcriptomic (by real-time 
PCR to analyze a potential residual mRNA expression level). We are presenting here 
the results of the validation of the ABCB5-knockout Mel-Juso cell line at the genomic 
level. The validation at the proteic level is being performed, but the results are not 
available yet. 
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3.1 Polyclonal cell populations 
 
We performed a first screening PCR after cells transfection with the CRISPR/Cas9 
system to analyze if the 53 kb or 125 kb fragment was successfully removed in several 
cells of the polyclonal population. For that purpose, the PCR primers have been chosen 
in such a way that the result of the PCR is positive only if the deletion occurred: F4 
and R15 to detect the 53 kb deletion and F4 and R27 to detect the 125 kb one. Under 
normal condition, both the reverse and the forward primers are too far from each other 
to make the amplification possible. In case of deletion, we expect that the mechanism 
of NHEJ DNA repair links together either the exons 4 and 15 or the exons 4 and 27, 
making the PCR primers close enough (i.e., separated from ∼ 300 bp) to allow the 
amplification. The results show, for both conditions, a band at the expected size of 300 
bp in the pool of transfected cells (TC) (Figure 15). 
However, we also observed several bands in the wild-type (WT) condition with 
sizes higher than the one corresponding to the detection of the 125 kb deletion (300 
bp). We have assessed the specificity of the F4/R27 pair of primers with the NCBI 
BLAST tool (available at: https://blast.ncbi.nlm.nih.gov/Blast.cgi). In the genomic 
database, the webtool identified nine target templates for this pair of primers that may 
induce non specific amplifications. In addition, the database indicates that all these 
unintended PCR products have expected lengths higher than 600 bp. 
 
Figure 15: Gel electrophoresis of PCR products using primers for the detection of the 53- or 125 
kb deletion. Ladder (L) 100 bp. Negative control (H20). Wild-type condition (WT). Detection of the 53 
kb deletion (left). Pool of transfected cells (TC): positive for the 53 kb deletion (∼ 300 bp). Detection 
of the 125 kb deletion (right). Pool of transfected cells (TC): positive for 125 kb deletion (∼ 300 bp). 
3.2 Monoclonal cell populations 
 
After detecting the 53 kb and 125 kb deletions in the polyclonal cell populations, the 
next step was to generate monoclonal cell populations to afterwards select those 
positive for one of these two deletions. We seeded transfected cells in 96-well plates 
at a density of one cell per well. After cell growing, we performed again a screening 
PCR on the collected monoclonal cell populations to identify those positives for the 
deletion of interest. We carried out a series of three PCRs on each tested clone: one 
PCR to identify if the 53 kb or 125 kb fragment was removed (following the same 
protocol than described in Section 3.1) and two PCRs to amplify each exon targeted 
by a gRNA (exons 4 and 15 or exons 4 and 27). Wild-type Mel-Juso cells serve as 
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negative control for the detection of the 53 kb or 125 kb deletion and as positive control 
for the amplification of each targeted exon. 
53 kb deletion. We screened nine monoclonal cell populations potentially positive 
for the deletion of 53 kb. The screening identified one positive clone, that we called 
HE (Figure 16). The results show a positive signal at the expected size of ∼ 350 bp in 
the HE condition, after the PCR performed to detect the 53 kb deletion, indicating that 
the fragment of 53 kb has probably been removed at least in one of the two alleles of 
ABCB5. The presence of a band at the expected sizes of 270 bp and 275 bp for the 
exons 4 and 15 confirms a monoallelic deletion of 53 kb in ABCB5 for the clone HE. 
In addition, we have sequenced the PCR product of the 53 kb deletion to identify the 
rattachment between both exons 4 and 15 after the mechanism of NHEJ DNA repair. 
The sequence was blasted with the NCBI BLAST tool. The database identified in the 
sequence a part of exon 4 deleted from 28 nucleotides followed by a part of the exon 
15 deleted from 23 nucleotides (Figure S1). 
 
From these results we conclude that in the clone HE a fragment of 53 kb has been 
removed from the ABCB5 gene in one allele. The other allele still contains both exons 
4 and 15 indicating that the clone carries a monoallelic deletion of 53 kb in ABCB5. A 
second round of transfection is required to generate biallelic deletion. 
 
 
Figure 16: Gel electrophoresis of PCR products using primers for exon 4 and exon 15 
amplification, and for the detection of the 53 kb deletion. Ladder (L) 100 bp. Negative control (H20). 
Wild-type (WT) condition: positive for exon 4 (270 bp) and exon 15 (275 bp) amplification. 
Heterozygous (HE) clone: positive for the amplification of exons 4 (270 bp) and 15 (275 bp), and for 
the detection of the 53 kb deletion (∼ 350 bp). 
We performed a second round of transfection on the clone HE in a similar way 
than for the first transfection. After the generation of monoclonal cell populations, we 
screened four clones (HO1; HO2; HO3; and HO4) potentially carrying the biallelic 
deletion of 53 kb in ABCB5. The results of the PCR indicate that the four clones tested 
are homozygous, as shown by: the absence of signal at 270 bp in the four conditions 
after the amplification of exon 4 (signal present in the wild-type (WT) and 
heterozygous (HE) conditions); the absence of signal at 275 bp in the four conditions 
after the amplification of exon 15 (signal present in the WT and HE conditions); and a 
positive signal at 350 bp in the four conditions after the amplification performed to 
detect the 53 kb deletion (signal present in the HE but absent in the WT condition) 
(Figure 17). We observe in the HE, HO1, HO2, and HO3 conditions a band at a length 
that does not correspond to the expected one for the exon 15. As the NCBI BLAST 
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tool does not identify any unintended target template within the genome for this pair 
of primers, it is likely that these aspecific bands are related to optimization of the PCR 
programme. 
We conclude that HO1, HO2, HO3, and HO4 have a biallelic deletion of 53 kb in 
ABCB5. A Western Blot is being performed on both Mel-Juso wild-type and ABCB5-
knockout Mel-Juso cells to validate these four ABCB5-knockout cell lines at the 
proteic level. 
 
Figure 17: Gel electrophoresis of screening PCR products using primers for exon 4 and exon 15 
amplification, and for the detection of the 53 kb deletion. Ladder (L) 100 bp. Wild-type condition 
(WT): positive for the amplification of exons 4 (270 bp) and 15 (275 bp). Heterozygous clone (HE): 
positive for the amplification of exons 4 (270 bp and 15 (275 bp), and for the detection of the 53 kb 
deletion (∼ 350 bp). Homozygous clones (H01, H02, H03, and HO4): positive for the detection of the 
53 kb deletion (∼ 350 bp). 
125 kb deletion. We screened 30 clones potentially positive for the 125 kb 
deletion. Two clones were identified as positives, that we called HE1 and HE2 (Figure 
18). The results show a positive signal at ∼ 300 bp in both the HE1 and HE2 conditions, 
indicating that the fragment of 125 kb has been removed at least in one of the two 
alleles of ABCB5. The presence of a band at the expected sizes of 270 bp and 280 bp 
for the exons 4 and 27 confirms the monoallelic deletion of 125 kb on HE1 and HE2. 
Following the results of the screening PCR, we chose the clone HE1 to perform the 
future analyses and we kept HE2 in backup. We sequenced the PCR product of the 125 
kb deletion to assess the rattachment between both exons 4 and 27 after the cleavage 
by Cas9 and the mechanism of NHEJ DNA repair. The sequence was blasted with the 
NCBI BLAST tool and the database identified in the sequence a part of the exon 4 
deleted from 38 nucleotides, directly followed by the last 17 nucleotides of the 
sequence of the exon 27 and the sequence of the intron located after the exon 27 
(Figure S2). 
We conclude that in the HE1 and HE2 clones, a fragment of 125 kb has been 
removed from the ABCB5 gene in one allele. The other allele still contains complete 
exons 4 and 27, indicating that the clones are heterozygous for the 125 kb deletion and 
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that a second round of transfection is required to obtain biallelic deletion. The latter is 
being undertaken, but the results are not available yet. 
 
 
Figure 18: Gel electrophoresis of PCR products using primers for exon 4 and exon 27 
amplification, and for the detection of the 125 kb deletion. Ladder (L) 100 bp. Wild-type (WT) 
condition: positive for the amplification of exons 4 and 27. Heterozygous clones (HE1 and HE2): 
positive for the amplification of exons 4 and 27, and for the detection of the 125 kb deletion. 
4. CRISPR/Cas9: efficiency for large genomic deletion 
 
The main problem of large-scale genomic deletions is that the larger is the size of the 
fragment to remove, the lower is the efficiency of the CRISPR/Cas9 system. The 
CRISPR/Cas9 tool is usually used in mammalian cells to produce single-site small 
indel mutations. Song et al. estimate that the efficiency of the method achieves 80% 
when only one gRNA is employed, but that the efficiency falls to less than 10% when 
the size of the deletion increases and when several gRNAs are used [89]. The results 
we obtained after the screening of the monoclonal populations confirm this low 
efficiency: on the nine clones tested for the 53 kb deletion, only one was identified as 
positive, giving an efficiency of 11%; on the 30 clones tested for the 125 kb deletion, 
two were positives, giving an efficiency of 6.7%. Moreover, all these positive clones 
only carried the large deletion in one of the two alleles of ABCB5. The four clones 
(HO1, HO2, HO3, and HO4) tested after the second transfection with the 
CRISPR/Cas9 system were all homozygous for the 53 kb deletion, giving an efficiency 
of 100%. However, this result is not really relevant due to the small sample size. It 
would be interesting to screen a larger number of clones to get more statistically 
relevant data about the method efficiency. 
 
Few papers provide methods to increase the efficiency of large genomic deletions 
using the CRISPR/Cas9 system. Han et al. show that the deletion efficiency may be 
doubled by using two different pairs of gRNAs. However, the major disadvantage of 
this technique is the increased number of potential off-targets and mutagenesis, which 
is due to the use of multiple gRNAs. Song et al. describe another technique that 
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currently remains hypothetical. It consists in directly targeting the mechanism of non-
homologous end joining DNA repair (NHEJ). They speculate that one of the reasons 
of the low efficiency of the CRISPR/Cas9-mediated large deletion is the tendency of 
the fragment deleted to be repaired by the mechanism of NHEJ. They suggest that the 
use of specific inhibitors targeting key molecules of the DNA repair pathway may 
decrease the rate of NHEJ repair events and may increase the efficiency of large 
genomic deletions by the CRISPR/Cas9 system [89]. 
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5. Subcellular fractionation 
 
The second part of this master thesis pursues the study of ABCB5 subcellular 
localization by the method of cell fractionation. The technique highly depends on the 
studied cell type and therefore the method may require several attempts to be 
optimized. As no data are available about previous complete cell fractionation on Mel-
Juso cells, we performed a first fractionation on the parental cell line to set up all the 
parameters of the technique. We are presenting here the results of this first 
fractionation through the establishment of the distribution profile of a series of 
enzymes and protein markers. In addition, we carried out a first detection of ABCB5 
among the different fractions by Western Blot. 
5.1 Distribution profiles of enzymes and protein markers 
 
We followed the protocol described by de Duve et al. [85] to perform the fractionation 
on the Mel-Juso cell line. The method firstly consists in lysing cells in a sucrose 
solution. Then, centrifugations with increasing speeds is performed to finally recover 
several fractions enriched in different organelles: nuclear (N), heavy mitochondrial 
(M), light mitochondrial (L), microsomal (P), and soluble (S) fractions. After 
collecting the fractions, we established the distribution profile of five enzymes and one 
protein markers of specific organelles: β-galactosidase (lysosome), alkaline α-
glucosidase (endoplasmic reticulum), cytochrome C oxidase (mitochondria), alkaline 
phosphodiesterase (plasma membrane), dipeptidyl-peptidase III (cytosol), and histone 
H1 (nucleus). 
The results are graphically presented in Figure 19. The surface of each block 
represents the percentage of activity of the enzyme within a fraction, whose the value 
is listed in the associated table to each graph. The x-axis corresponds to the percentage 
of proteins (% proteins) within a specific fraction. The y-axis represents the specific 
relative activity (SRA) of the enzyme within a fraction, also called the enrichment of 
the enzyme within this fraction. It is calculated by dividing the percentage of activity 
of the enzyme by the percentage of proteins found in the fraction. 
β-galactosidase. The β-galactosidase is a lysosomal enzyme. The lysosomes 
mainly sediment in the L fraction. The enzymatic dosage detects activity of the β-
galactosidase among all the different fractions, with the majority of activity in the L 
fraction (43.63%). There is an enrichment of the enzyme in the L fraction, as shown 
by the SRA of 20.64. The enrichment is particularly important: the purity of the 
fraction is high. Data from previous fractionations in other cell types show that usually 
the SRA of the β-galactosidase in the L fraction turns around 10. The detection of 
lysosomal activity in the N fraction (where we expect only to retrieve nuclei) is not 
coherent and one hypothesis of this result is explained below. 
Alkaline α-glucosidase. This enzyme is a marker of the endoplasmic reticulum. 
The first step of fractionation consists in lysing cells. It induces the break of the 
endoplasmic reticulum that subsequently forms small vesicles called microsomes. As 
these vesicles mainly sediment in the P fraction which contains the majority of the 
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microsomes, we expect to retrieve most of the alkaline α-glucosidase activity in this 
specific fraction. However, the results show a distribution of the enzymatic activity 
among all the fractions with the greatest activity in the N fraction (37.88%) followed 
by the P fraction (22.10%). We speculate that the high percentage in N may be due to 
large amounts of rough reticulum endoplasmic (RER) that continuous the outer nuclear 
membrane or to insufficient cell lysis (described below). Finally, we do not observe 
any significant enrichment of the enzyme within one of the five fractions, as shown by 
the quite similar SRA among the N, M, L, and P fractions (1.41; 2.43; 2.15; and 1.53 
respectively). Unlike the β-galactosidase, the alkaline α-glucosidase does not present 
a very specific distribution profile. 
Cytochrome C oxidase. The cytochrome C oxidase is a marker of mitochondria. 
This organelle may be subdivided between heavy- and light mitochondria. The heavy 
mitochondria are larger in size and volume. They have a higher sedimentation 
coefficient and are consequently mainly retrieved within the M fraction [93]. The light 
mitochondria are smaller in size and volume, and are usually collected in the L fraction. 
The results show a majority of cytochrome C oxidase activity within the M fraction 
(59.67%) and an enrichment of the enzyme within this specific fraction (SRA of 7.29). 
Although the enzymatic activity is low in the L fraction (6.92%), the enrichment of the 
enzyme within the fraction is 3.27. Finally, the detection of cytochrome C oxidase in 
the N fraction is less coherent, but one hypothesis about this result is described below. 
Alkaline phosphodiesterase. This enzyme is a marker of the plasma membrane. 
Similarly to the endoplasmic reticulum, the step of cell lysis promotes the break of 
plasma membranes that subsequently form small vesicles. These vesicles may vary in 
size, i.e. the distribution profile of the alkaline phosphodiesterase is variable and 
depends on the intensity of cell lysis. However, in most cases, these plasma membrane 
vesicles sediment in the P fraction in which we find the microsomes. Our results are 
consistent with these data, as shown by the majority of alkaline phosphodiesterase 
activity detected in the P fraction (32.02%). However, we also detect activity in the 
heavier fractions (L, M, and N), with an enrichment of the enzyme in the L fraction 
(SRA of 8.43). The presence of plasma membrane in both M and L fractions may be 
due to larger plasma membrane vesicles that have sedimented in these specific 
fractions. The detection of alkaline-phosphodiesterase activity in the N fraction is less 
coherent and one hypothesis for this result is described below. 
Dipeptidyl-peptidase III. This enzyme is a soluble enzyme found in the cytosol: 
we expect to detect the majority of enzymatic activity in the S fraction that contains 
all the non-sedimentable particles. The results show a high percentage of activity in 
this S fraction (65.71%). However, we also detect some activity in all the other 
fractions. One hypothesis for the presence of dipeptidyl-peptidase III in both the M 
and L fractions is the presence of autophagic vesicles. During the process of 
autophagy, a part of the cytosol is bundled within autophagic vesicles that belongs to 
the lysosomal system, i.e., they mainly sediment in the M and L fractions. It is possible 
that the vesicle cargo contains a certain amount of dipeptidyl-peptidase III, explaining 
the presence within these fractions. However, the presence of enzymatic activity in the 
N fraction is less coherent and is explained below. 
52 
Histone H1. The histone H1 is a protein marker of the nucleus which can be 
detected by Western Blotting. We have detected the histone H1 protein at the expected 
size of 37 kDa with an anti-histone H1 monoclonal antibody. The results show an 
intense signal size in the N fraction and a very low signal in the M and P fractions. The 
E fraction corresponds to the supernatant recovered after the first step of 
centrifugation, i.e., all the cell lysate without the nuclei. The absence of detection of 
histone H1 in the E fraction is consistent and indicates that the nuclei have been 
entirely separated from the cell lysate. Following the Western Blot, we have quantified 
the histone H1 signals using the ImageJ software to graphically obtain the distribution 
profile of the protein marker. The amount of protein is almost entirely found in the N 
fraction, with a percentage of 98.71%. 
Regarding these results, we have identified one parameter to optimize for the future 
fractionations of the Mel-Juso cell line. We have detected for all enzyme markers a 
percentage of activity in the N fraction. We hypothetize that it is due to the presence 
of unbroken cells in this specific fraction. We performed two series of six passages in 
the Dounce homogeneizer to lyse the cells but this number is probably insufficient to 
lyse all the cells. For the next fractionation, we will slightly increase this number to 
ten passages. However, it is important to be aware that each cell type presents different 
degree of sensitivity to the mechanism of lysis. The process must be carefully 
balanced: if the lysis is too strong, the risk is to also break the nucleus and to release 
fragments of DNA within all the different fractions. Finally, we could also establish 
the distribution profile of the Golgi apparatus and the peroxisome. Specific enzyme 
markers exist for these two organelles, i.e. the galactosyl transferase and the catalase.  
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 (a) (b) 
 
 (c) (d) 
 
 (e) (f) 
Figure 19: Subcellular fractionation on Mel-Juso parenteral cells by differential centrifugation. 
Series of enzymatic assays to establish the distribution profile of the β-galactosidase (lysosome) (a), the 
alkaline α-glucosidase (endoplasmic reticulum) (b), the cytochrome C oxidase (mitochondria) (Cytox), 
the alkaline phosphodiesterase (plasma membrane) (d), and the dipeptidyl-peptidase III (cytosol) (e) 
among the different fractions. Western Blotting and quantification by ImageJ to establish the 
distribution profile of histone H1 (nucleus) (f). x-axis: percentage of proteins (% proteins) within a 
specific fraction; y-axis: specific relative activity (SRA) of the enzyme within the fraction, i.e. the 
enrichment of the enzyme in this specific fraction. Calculated by dividing the percentage of activity of 
the enzyme by the percentage of proteins within the fraction. y-axis for histone H1: relative specific 
signal (RSS) as the protein does not have enzymatic activity. Surface of each block: percentage of 
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activity of the enzyme within a specific fraction. The percentage are listed in the associated table for 
each enzymatic dosage. 
5.2 Distribution profile of ABCB5 
 
The results of the real-time PCR have shown that Mel-Juso cells at least express 
ABCB5 under the β isoform (Section 1.1). The size of the protein is estimated at 90 
kDa and we have performed a Western Blot to detect the ABCB5 protein among the 
different fractions. The anti-ABCB5 polcylonal antibody (Rockland, 600-401-A77S) 
was used to identify the protein. 
The results show a band at 90 kDa in the cell lysate (E) and in the nuclear (N) and 
microsomal (P) fractions (Figure 20). The complete absence of signal in the L fraction 
indicates that ABCB5β is probably not a lysosomal transmembrane protein. We 
hypothetize that the transporter is at least located in the nuclear membrane, as shown 
by the intense signal observed in the N fraction that contains the majority of the nuclei. 
These data are supported by previous studies that identified another ABC transporter 
(ABCB1) in the nuclear membrane of human breast cancer cells (MCF-7) and human 
colon cells (LoVo cell line) [94, 95]. As both ABCB1 and ABCB5 have 73% of 
structure homology, it is plausible that ABCB5 is found within the nuclear membrane. 
The detection of ABCB5 in the P fraction only provides insights about potential other 
subcellular localizations of the transporter. This fraction contains the majority of 
microsomes that originate from fragments of the plasma membrane, the endoplasmic 
reticulum, but also the Golgi apparatus. It would be relevant to perform a sub-
fractionation on this specific fraction (e.g., by using a sucrose density gradient 
separation) to isolate each organelle and more precisely define the localization of 
ABCB5. Moreover, early melanosomes could also be present in the P fraction. It would 
be interesting to establish the distribution profile of the organelle among all the 
fractions by using the gp100 glycoprotein as protein marker. As Chen et al. have 
already hypothetized that ABCB5 could be involved in melanogenesis, we cannot 
exclude that the transporter is located within this specific organelle [65].  
However, we must carrefully interpret these data and must be aware that it remains 
hypothetical. The anti-ABCB5 antibody used shows a lack of specificity and 
recognizes many other proteins. Even if these results are consistent with those 
previously described by Sana et al. (i.e., a mixed localization of ABCB5 both in N and 
P fractions), we cannot conclude that the observed bands correspond to ABCB5. Until 
now, there is no trustworthy ABCB5 negative control in mammalian cells to prove the 
specificity of this antibody.  
These results show the interest to use, in this specific case, the ABCB5-knockout 
cell line as a robust negative control. As already mentioned, the validation at the proteic 
level of the ABCB5-knockout cell line by Western Blot is being performed. This 
Western Blot is simultenaeously performed on ABCB5-expressing and ABCB5-
knockout Mel-Juso cells. We expect that the synthesis of ABCB5 is completely 
inhibited in the knockout cell line. Thereby, the specificity of the anti-ABCB5 
antibody will be validated if we detect a signal at 90 kDa in the ABCB5-expressing 
cells that is absent from the ABCB5-knockout cell line. Afterwards, the purpose is to 
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perform a second fractionation simultaneously on both ABCB5-expressing and 
ABCB5-knockout cells to strenghten and validate the data about the localization of the 
transporter among the different fractions. 
 
Figure 20: Detection of ABCB5 by Western Blotting following Mel-Juso subcellular fractionation. 
Detection of ABCB5β (90 kDa) using the anti-ABCB5 polyclonal antibody from Rockland (600-
401A77S). Ladder (kDa); ABCB5β transfected-High-5 insect cells as positive control (C+); non-
transfected High-5 insect cells as negative control (C-). Mel-Juso cell lysate (E), nuclear (N), heavy 
mitochondrial (M), light mitochondrial (L), microsomal (P), and soluble (S) fractions. 
Other techniques have already been tested to detect the ABCB5 transporter without 
the need to use anti-ABCB5 antibodies. Specific tags such as the eGFP can be used to 
generate a fusion protein with the ABCB5 transporter. However, such a large tag can 
render the protein non-functional and bias its localization. Therefore, we decided to 
work from the native protein.  
 
The firm Promega has developed a method called Nano-Glo HiBiT blotting 
system. The method allows to easily visualize HiBiT-tagged proteins on a membrane, 
after gel separation. For that, a blotting reagent containing both the LgBiT protein and 
the furimazine substrate is added to the membrane. The HiBiT tag is able to bind with 
high affinity to the LgBiT protein that together form a complex having a luciferase 
activity. In presence of the furimazine substrate, the complex releases a luminescence 
signal that can be detected on the membrane. This alternative technique might be 
powerful to detect the ABCB5 transporter without the use of anti-ABCB5 antibodies. 
Compared to other existing tags, the HiBiT tag has several advantages: the small size 
of the tag (1.3 kDa) allows to directly insert it within the endogenous protein thanks to 
the CRISPR/Cas9 tool, meaning that the technique does not require cloning 
procedures; the size of the tag decreases the risk of changes in the protein conformation 
that may lead to protein mislocalization. Moreover, the technique is highly sensitive 
and quantitative as the luminescence signal is directly proportional to the luciferase 
activity. Finally, in contrary to anti-ABCB5 antibodies that recognize many other 
proteins, the background noise with this alternative technique would be probably very 
low.  
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Conclusions and perspectives 
1. ABCB5-knockout cell line 
 
The first part of this master thesis aimed to generate an ABCB5-knockout cell line to 
use it as a tool to pursue the characterization of the ABCB5 transporter. We chose as 
model the Mel-Juso unpigmented primary melanoma cells that at least expresses the 
ABCB5 transporter under the β isoform. We employed the CRISPR/Cas9 genome-
editing tool to remove either a fragment of 53 kb or 125 kb in the ABCB5 gene. For 
that purpose, three guide RNAs have been designed with high on-target specificity and 
low risk of off-target effects. After a first round of transfection, clonal expansion, and 
screening PCR we achieved to generate clones with a monoallelic deletion of 53 kb or 
125 kb in ABCB5. A second round of transfection allowed us to successfully recover 
four clones with a biallelic deletion of 53 kb. To date, these clones have been validated 
at the genomic level (by screening PCR and sequencing). The validation at the proteic 
level (by Western Blot) is currently being undertaken to confirm that the protein 
synthesis of both the ABCB5 full-length and β isoforms is inhibited. The second 
transfection that will provide a Mel-Juso cell line with a biallelic deletion of 125 kb is 
in progress. This cell line will be entirely depleted from the ABCB5 gene, preventing 
both the mRNA transcription and the protein synthesis. These two parameters will be 
validated by Western Blot and real-time PCR. 
Our results demonstrate that the CRISPR/Cas9 is a powerful tool to precisely edit 
and modify genes of interest, thanks to the design of specific gRNAs. Although most 
of the studies in mammalian cells used the CRISPR/Cas9 tool to induce small indel 
mutations at single-site, we have shown that it is also suitable to remove large-scale 
genomic regions from over 100 kb. This purpose may be achieved by co-transfecting 
cells with several gRNAs. 
The ABCB5-knockout Mel-Juso cell line constitutes a powerful model that open 
the field to new research to characterize the ABCB5 transporter, mainly by loss-of-
function gene studies. As previously mentioned, the role of ABCB5 in melanoma 
chemoresistance has been well described: the transporter mediates the efflux of a wide 
range of anti-cancer drugs out of the cell. However, there is now emerging evidence 
of an additional role of ABCB5 in melanomagenesis. This role in tumorigenesis would 
be drug-efflux independent and directly related to the efflux of endogenous substrates 
such as metabolites, signaling molecules, etc. To date, data remain controversial: some 
papers describe ABCB5 as an oncogene, promoting tumor progression and metastases; 
other studies suggest that ABCB5 acts as a tumor suppressor, preventing tumor 
initiation through the inhibition of cell proliferation. However, we cannot exclude that 
the role of ABCB5 in melanomagenesis is cell type specific: the oncogenic role of 
ABCB5 has been described in a population of malignant-melanoma initiating cells 
(MMICs) although the role as tumor suppressor in non-MMICs. 
It will be interesting to perform a series of functional assays on both the ABCB5-
expressing and ABCB5-knockout Mel-Juso cell lines to identify a role of ABCB5 as 
tumor suppressor in this specific cell type. Proliferation assays, anchorage independent 
growth assays, migration and invasion assays, etc. are all tests that can be performed 
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in vitro to study some hallmarks of cancer and elucidate the role of ABCB5 in 
melanomagenesis. Before starting all these functional assays, one important step is to 
sequence all the off-targets sites to detect potential mutations that could interfere with 
the results of the analyses.   
Another interesting field would be to study the role of ABCB5 in the adaptation of 
cancer cells metabolism. This adaptation is directly related to the tumor environment 
(e.g., hypoxia) and is essential for tumor growth, survival, proliferation, and 
maintenance. Among those, increasing the rate of glycolysis and limiting oxidative 
phosphorylation is one of the most frequent mechanism of adaptation and is known as 
the Warburg effect [96]. In 2016, Lutz et al. established the metabolic profiles for two 
groups of human G3361 malignant-melanoma initiating cell lines: the first condition 
expressing ABCB5 and the second one knockdown for the transporter expression by 
the use of shRNA. The results showed significantly higher levels of several compounds 
involved in the glycolytic pathway in the ABCB5-expressing G3361 melanoma cells 
compared to the ABCB5-knockdown condition, suggesting a potential role of ABCB5 
in increasing the rate of the glycolytic pathway in this specific subpopulation of cancer 
stem cells. The molecular mechanism remains unclear but researchers suggest that this 
upregulation may result from an ABCB5/IL-1β/HIF-1α/PFKP signaling cascade. The 
metabolomic analysis has been carried out on the G3361 malignant-melanoma 
initiating cells (i.e., cancer stem cells) and researchers pointed out the interest to 
perform a similar study on additional melanoma cell lines expressing ABCB5. As the 
Mel-Juso cells are not cancer stem cells, this kind of study will allow to assess if the 
effects of ABCB5 on the cellular metabolism are similar or different from those 
observed in the G3361 cell line. 
Here we have shown that studying the role of ABCB5 in melanomagenesis is one 
example of all the potential applications that provides the generation of the ABCB5-
knockout MelJuso cell line. Other fields of research may be explored such as: drug-
sensitivity assays, substrates transport assay, proteomic analysis, etc. 
2. ABCB5 subcellular localization 
 
The second part of this Master Thesis aimed to study the ABCB5 subcellular 
localization by the method of cell fractionation described by de Duve et al.. As the 
technique highly depends on the studied cell type, we performed a first fractionation 
on the parental Mel-Juso cell line to set up and optimize all the parameters of the 
technique. After lysing the cells in sucrose solution, we used sequentially increasing 
speeds of centrifugation to recover a total of five fractions enriched in specific 
organelles: nuclear (N), heavy mitochondrial (M), light mitochondrial (L), microsomal 
(P), and soluble (S) fractions. A series of enzymatic assays and one immunoblotting 
allowed us to establish the distribution profiles of enzyme and protein markers of 
specific organelles through the different fractions. 
Overall, the results have shown a coherent distribution profile of these enzymes 
and protein markers, but the detection in the nuclear fraction of activity for all the 
tested enzymes seems to indicate the presence of intact cells in this specific fraction. 
For the future fractionations, a slight increase from six to ten in the number of Dounce 
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passages will probably be sufficient to lyse all the cells without the risk to also break 
nuclei. 
In addition, we have established a first distribution profile of ABCB5 after 
identifying the protein by Western Blot. We have detected an enrichment of ABCB5 
both in the nuclear and microsomal fractions suggesting that ABCB5 has a mixed 
localization. Further steps of purification would be necessary in the P fraction to better 
define the transporter localization in the endoplasmic reticulum, the plasma membrane, 
the Golgi apparatus, or the early melanosomes. Even if these results are consistent with 
data from previous cell fractionation, they remain hypothetical. The anti-ABCB5 
antibody used presents a lack of specificity for the transporter, as shown by the 
recognition of many other proteins. A trustworthy negative control in mammalian cells 
is needed to prove and validate the specificity of this antibody. Our engineered 
ABCB5-knockout Mel-Juso cell line constitutes a robust tool to assess this specificity. 
The proteic validation (i.e. by Western Blot) of the ABCB5-knockout cell line is being 
undertaken and will allow us to prove the specificity of the antibody. Afterwards, a 
second set of fractionations will be carried out simultaneously on both the ABCB5-
expressing and ABCB5-knockout Mel-Juso cell line to strenghten the data about the 
transporter localization. However, we also have considered other methods to detect the 
ABCB5 transporter, without the need to use anti-ABCB5 antibodies. Among those, 
the HiBiT technique developed by Promega could be suitable and could constitute a 
relevant alternative because the method is highly sensitive and quantitative. 
The cell fractionation by differential centrifugation (i.e. de Duve’s method) gets a 
first insight about the transporter localization, by determining which fractions are 
enriched for ABCB5. However, this technique does not provide pure organelles 
fractions and we will perform further steps of purification using equilibrium density-
gradient centrifugation. The method separates the organelles according to their density. 
It consists in establishing a sucrose density gradient and to subject the fraction to a 
very high centrifugal force (usually 15,000 g). The organelles sediment until they reach 
the layer of the sucrose gradient corresponding to their own density. The technique is 
useful to separate the rough endoplasmic reticulum from the Golgi apparatus and the 
plasma membrane. This property is particulary interesting as these organelles are 
mainly found in the microsomal fraction (P), in which we hypothetize that ABCB5 is 
also localized.  
Finally, we must bear in mind that the subcellular localization of ABCB5 could be 
cell specific. Identifying the localization of ABCB5 in Mel-Juso cells will help to 
better understand the role of the transporter in melanoma cells. However, the 
transporter is also expressed in other cell types (e.g., human testis), in which we cannot 
exclude a different subcellular localization of the transporter. The subcellular 
localization of ABCB5 is crucial to further study the role of the transporter at the 
intracellular level, to assess potential interactions of ABCB5 with other proteins, etc.  
 
This Master Thesis will have contributed to pave the way toward the 
characterization of the ABCB5 transporter in engineering an ABCB5-knockout human 
melanoma cell line, which will be used as a robust negative control. 
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Supplementary Material 
 
 
Figure S1: Results of the sequencing of the PCR product for the detection of the 53 kb deletion. 
The sequencing of the PCR product confirms the rattachment between both exons 4 and 15, following 
the cleavage by the CRISPR/Cas9 system. The exon 4 (purple) is deleted from 28 nucleotides and 
directly followed by a part of the exon 15 (red) deleted from 23 nucleotides. The results of the 
sequencing have been analyzed with the NCBI BLAST tool. 
 
 
Figure S2: Results of the sequencing of the PCR product for the detection of the 125 kb deletion. 
The sequencing of the PCR product confirms the rattachment between both exons 4 and 27 after the 
cleavage by the CRISPR/Cas9 system. The exon 4 (purple) is deleted from 38 nucleotides and directly 
followed by the last 17 nucleotides of exon 27 (red) and the sequence of intron (green). The results of 
the sequencing have been analyzed with the NCBI BLAST tool. 
